ADT 0
AS 0
BCR 0
biochemical 0
CaP 0
Hopkins 0
Johns 0
lethal 0
PC 0
PCa 0
prostate 0
Prostate 0
prostatectomy 0
PSADT 0
RP 0
triggered 0
ZFP36 0
0.862 1
24.0% 1
28.8% 1
34.9% 1
42.5% 1
54.2% 1
58.4% 1
70.5% 1
706 1
76.6% 1
77.3% 1
budding 1
cause-specific 1
Controlling 1
CRM 1
Depth 1
ECS 1
HRS 1
Invasion 1
LNs 1
LRFS 1
LT 1
LVI 1
Lymph 1
lymphovascular 1
Nodal 1
pN1 1
pN2 1
reclassified 1
removed 1
thickness 1
TNM 1
When 1
Aaron 2
Alto 2
Angeles 2
Aviv 2
CA 2
California 2
Carolina 2
Cedars-Sinai 2
Chapel 2
Chase 2
Colorado 2
Comprehensive 2
Davis 2
Diego 2
Duarte 2
Duke 2
Durham 2
Elizabeth 2
Erin 2
Fox 2
Francisco 2
Guidelines 2
Helen 2
Hill 2
Hope 2
Jolla 2
Kaiser 2
Kansas 2
Karen 2
KS 2
La 2
Large 2
Levine 2
Lineberger 2
Los 2
Miami 2
MO 2
Monica 2
Moores 2
NC 2
Nijmegen 2
Palo 2
Perez 2
Philadelphia 2
Racial 2
Sacramento 2
San 2
Stanford 2
Sylvester 2
Tel 2
Transplantation 2
VA 2
Veterans 2
W. 2
Wong 2
121 3
atezo 3
matched 3
MDC 3
Access 4
Administration 4
Agency 4
applications 4
approval 4
approvals 4
approved 4
biologics 4
comprise 4
Davidoff 4
Drug 4
England 4
entities 4
FDA 4
Food 4
HTA 4
Israel 4
mandated 4
mNSCLC 4
Petah 4
publications 4
real-world 4
Scotland 4
Silver 4
Spring 4
submitted 4
Tikva 4
trials 4
U.S. 4
USA 4
344 5
antineoplastic 5
APM 5
class 5
direct 5
disease-specific 5
disrupting 5
DS-8201a 5
Evidence 5
gamma 5
humans 5
ICONIC 5
individually 5
JTX-2011 5
MHC 5
molecules 5
Myc 5
raised 5
regulatory 5
sensitization 5
tar 5
AOC 6
CRx 6
cystectomy 6
deb 6
dysplasia 6
excision 6
gp 6
iodine 6
IVA 6
lowing 6
Lugol 6
macroscopic 6
modality 6
neo-adj 6
neo-adjuvant 6
operable 6
OvCa 6
PSCC 6
pStage 6
resection 6
surg 6
surgical 6
surgically 6
Sx 6
AKT1 7
AKT2 7
Alterations 7
altered 7
ccfDNA 7
CCNE1 7
CMC 7
CNVs 7
codon 7
Complex 7
co-mutations 7
CTNNB1 7
detected 7
E545K 7
EGFR-mt 7
exclusive 7
fashion 7
FBXW7 7
founder 7
frequencies 7
G12D 7
G12V 7
IDH2 7
Interestingly 7
KRAS 7
KRAS-mutant 7
MC1 7
MLL2 7
mu 7
Mut 7
mutants 7
mutated 7
Mutated 7
mutations 7
Mutations 7
mutually 7
NOTCH1 7
NRAS 7
PIK3R1 7
RASA1 7
RB1 7
S310F 7
tation 7
tations 7
TMBH 7
TMBI 7
TP53 7
truncating 7
V600K 7
wild-type 7
wt 7
abemaciclib 8
During 8
F 8
Japanese 8
Prophylactic 8
Pulmonary 8
According 9
committee 9
data 9
Data 9
entered 9
EU 9
included 9
inconsistent 9
intention-to-treat 9
methodology 9
pathologists 9
pooled 9
publication 9
random 9
registered 9
registration 9
reviewers 9
reviews 9
Since 9
yearly 9
AJ 10
ancestry 10
ascertainment 10
carrier 10
counseling 10
counselling 10
dergoing 10
DSE 10
ENGAGE 10
families 10
family 10
forms 10
genetic 10
genetics 10
GT 10
HBOC 10
in-person 10
IPD 10
MGPT 10
multi-gene 10
multigene 10
non-AJ 10
oncologist-led 10
panel 10
panels 10
PCA 10
personal 10
referrals 10
relatives 10
request 10
screener 10
susceptibility 10
testing 10
TMP 10
yield 10
Adjusted 11
CIs 11
confidence 11
Gray 11
Hazard 11
HRa 11
HRs 11
interval 11
intervals 11
Odds 11
ORs 11
ratio 11
ratios 11
STD 11
budget 12
cost 12
Cost 12
cost-effective 12
cost-effectiveness 12
costs 12
DAR 12
dollars 12
effectiveness 12
Effectiveness 12
expensive 12
gained 12
HCP 12
ICER 12
incorporated 12
incremental 12
Incremental 12
life-years 12
Markov 12
MMS 12
NMA 12
perspective 12
probabilistic 12
probabilities 12
QALY 12
quality-adjusted 12
saved 12
societal 12
SR 12
WTP 12
Almost 13
appointment 13
averaging 13
awareness 13
benchmark 13
CEASE 13
COs 13
dates 13
disagreed 13
discussion 13
donate 13
endorsed 13
failures 13
fear 13
half 13
held 13
hospitalists 13
HSAs 13
hypothetical 13
Implementation 13
intensivists 13
materials 13
MDs 13
mendations 13
MGTP 13
minor 13
money 13
MOs 13
nurses 13
office 13
oncologist 13
oncologists 13
opinion 13
paid 13
pharmaceutical 13
PTs 13
recommendations 13
Recommendations 13
resources 13
SBI 13
scenarios 13
SCP 13
shortages 13
spent 13
stated 13
statements 13
substitute 13
substitution 13
travel 13
vast 13
voting 13
ALP 14
BAT 14
BST 14
Clinically 14
decline 14
flare 14
mary 14
minimally 14
neurological 14
Pain 14
PCWG2 14
pri 14
prolongation 14
PSA50 14
Ra223 14
radiographic 14
Reported 14
seizures 14
symptomatic 14
worsened 14
anamorelin 15
BMI 15
body 15
cachexia 15
Changes 15
weight 15
After 16
Before 16
Biopsies 16
completed 16
completing 16
completion 16
consent 16
icity 16
initially 16
initiation 16
intolerance 16
minimum 16
monitored 16
randomization 16
reason 16
Reasons 16
start 16
started 16
Stratification 16
till 16
whichever 16
withdrawal 16
withdrew 16
006 17
035 17
47.2% 17
64.7% 17
70.8% 17
760 17
ACA-DCE 17
BSA 17
Compared 17
CwC-1 17
CwC-2 17
disability 17
discharge 17
discharged 17
facilities 17
Having 17
hospice 17
insurance 17
insured 17
IPC 17
Latino 17
LEC 17
LI 17
life-extending 17
manufacturer 17
Medicaid 17
non-L 17
nursing 17
odds 17
pct 17
pre-ACA 17
preventable 17
private 17
readmission 17
readmissions 17
siblings 17
surance 17
uninsured 17
Uninsured 17
USL 17
widowed 17
AAML1031 18
administration 18
Aflac-AML 18
anthracycline 18
Bv 18
ceived 18
chemosensitive 18
courses 18
craniospinal 18
CYC 18
DOXO 18
DXRZ 18
exceeding 18
fourth 18
HDMTX 18
high-dose 18
ifosfamide 18
LR-AML 18
MAP 18
methotrexate 18
MP 18
MTX 18
Ommaya 18
preceded 18
preceding 18
regimen 18
rescue 18
Rituximab 18
tolerate 18
vincristine 18
zolomide 18
420 19
560 19
alternating 19
ASH 19
CIA 19
Clad 19
crenolanib 19
del17p 19
eNDMM 19
factorial 19
FCR 19
filgrastim 19
FR 19
guadecitabine 19
HCVAD 19
ibr 19
Ibr 19
ibrutinib 19
Ibrutinib 19
Ida 19
idarubicin 19
iFCG 19
non-del 19
obinutuzumab 19
ofa 19
OPTIMAL 19
prophylaxis 19
RICOVER-60 19
SGI5 19
TGR-1202 19
UTX 19
ven 19
xCHOP-14 19
735 20
cavity 20
excluding 20
hypopharynx 20
larynx 20
lip 20
mouth 20
N1 20
nasopharynx 20
ND 20
OP 20
oro 20
pack 20
pharynx 20
T3 20
T4 20
tongue 20
ascertained 21
Court 21
dividuals 21
evolved 21
familial 21
Germline 21
hereditary 21
Identifying 21
IMFS 21
implications 21
inherited 21
Knowledge 21
MSK 21
Next-generation 21
PND 21
predisposition 21
Rare 21
Recurrent 21
Supreme 21
suspicion 21
Syndrome 21
syndromes 21
well-characterized 21
What 21
aspiration 22
automated 22
biopsies 22
biopsy 22
cessful 22
converted 22
core 22
Diagnostics 22
EAC 22
embedded 22
endoscopic 22
fixed 22
fluorescence 22
FNA 22
foci 22
formalin 22
fresh 22
frozen 22
harvested 22
image 22
Immunohistochemistry 22
mandatory 22
material 22
MBq 22
microscopy 22
mode 22
mTc-IL2 22
needle 22
optional 22
paraffin 22
post-NAC 22
pPROG 22
pre-treatment 22
PROG 22
resections 22
route 22
suc 22
sufficient 22
suitability 22
TCH 22
TCHL 22
technique 22
tissue 22
Tissue 22
FBC 23
MBC 23
non-MBC 23
TS 23
ADJ 24
allo 24
allogeneic 24
alloHCT 24
allo-SCT 24
alloSCT 24
auto 24
autoHCT 24
donor 24
graft 24
GVHD 24
HCT2 24
HCT 24
InO 24
intensity 24
MSD 24
MUD 24
non-relapse 24
NRM 24
relapse 24
relapses 24
RIC 24
SCT 24
transplant 24
Transplant 24
transplants 24
TRM 24
yr 24
40 25
50 25
60 25
62.0 25
65 25
68 25
70 25
75 25
80 25
85 25
median 25
Median 25
range 25
yrs 25
adverse 26
AE 26
AEs 26
alopecia 26
anemia 26
Anemia 26
anorexia 26
asthenia 26
Aza 26
blin 26
bocytopenia 26
chills 26
constipation 26
cough 26
DB 26
dermatitis 26
diarrhea 26
Diarrhea 26
discon 26
dysphagia 26
elsiglutide 26
emergent 26
emesis 26
episodes 26
esophagitis 26
events 26
fatigue 26
febrile 26
GGT 26
Gr2 26
Gr 26
Gr3 26
Grade 26
Grades 26
hand-foot 26
Hematological 26
Hypertension 26
hypertriglyceridemia 26
hyponatremia 26
Infections 26
leucopenia 26
leukopenia 26
lymphopenia 26
maculopapular 26
max 26
mucositis 26
myelosuppression 26
nausea 26
Nausea 26
neutropenia 26
Neutropenia 26
non-hematological 26
non-heme 26
on-study 26
paronychia 26
pneumonia 26
Pneumonitis 26
pyrexia 26
Rash 26
reactions 26
Related 26
SAEs 26
Serious 26
stomatitis 26
TEAE 26
TEAEs 26
thrombocy 26
thrombocytopenia 26
Thrombocytopenia 26
tinuation 26
topenia 26
toxicities 26
Toxicities 26
transaminase 26
treatment-emergent 26
tropenia 26
tx-related 26
vomiting 26
Affairs 27
Award 27
Beaumont 27
Bethesda 27
biobank 27
BMT 27
Branch 27
Brown 27
Cancer 27
Christine 27
Christopher 27
Community 27
Consortium 27
Dana 27
Farber 27
Greenville 27
Health 27
Institutes 27
Integrated 27
introduced 27
Janssen 27
LLC 27
Na 27
National 27
Nationwide 27
Nicole 27
Oklahoma 27
Oregon 27
Personalized 27
Pharmacy 27
Population 27
Program 27
Project 27
Public 27
Rockville 27
Scientific 27
tology 27
Training 27
UCSD 27
Urology 27
1839 28
amcasertib 28
ated 28
BBI-608 28
encouraging 28
Encouraging 28
Ib 28
napabucasin 28
Napabucasin 28
paz 28
pre-treated 28
PTX 28
signs 28
stemness 28
toler 28
A-based 29
aiming 29
alternative 29
assessing 29
avoiding 29
chemotherapy-induced 29
compromise 29
conducting 29
confirming 29
cooling 29
demonstrate 29
designs 29
dition 29
ef 29
efficiency 29
feasibility 29
fective 29
maintain 29
optimum 29
pilot 29
possibility 29
preservation 29
prevent 29
preventing 29
prospective 29
RCT 29
rich 29
scalp 29
studies 29
This 29
undergoing 29
AZD3759 31
barrier 31
BBB 31
blood-brain 31
cross 31
develops 31
effectively 31
EGFRm 31
emergence 31
leptomeningeal 31
meningiomas 31
NCT02228369 31
neratinib 31
progressed 31
recur 31
recurrent 31
TKI-na 31
TTFields 31
Ab 32
antigen-specific 32
anti-NY-ESO-1 32
catabolism 32
CD107a 32
CD137 32
CETCs 32
ch14 32
chemokine 32
CHO 32
co-cultured 32
Consistent 32
CT26 32
CTL 32
CTLA4 32
effector 32
GITR 32
H1128-IL12 32
IDO1 32
IFN-g 32
IFNg 32
IgG 32
IL2 32
intra-tumoral 32
kynurenine 32
leukocytes 32
macrophage 32
MC38 32
MCPyV-specific 32
MHCI 32
Mice 32
mRNAs 32
OX40 32
PAP 32
parental 32
PBS 32
percentages 32
pSTAT3 32
PVRIG 32
remarkably 32
STAT3 32
stronger 32
subQ 32
suppressive 32
syngeneic 32
T-ex 32
Th1 32
THU-Dec 32
TLA 32
Treg 32
up-regulation 32
upregulation 32
00 33
287 33
AM-11 33
AM-12 33
confirm 33
confirmatory 33
Discussed 33
Discussion 33
Displayed 33
Effect 33
Effects 33
elucidate 33
exploration 33
exploring 33
findings 33
formation 33
Further 33
Health-related 33
investigation 33
larger 33
Larger 33
merit 33
NCT02178722 33
Ongoing 33
Oral 33
PM-6 33
support 33
Unassigned 33
underway 33
warrant 33
warranted 33
warrants 33
accompanied 34
appearance 34
compartment 34
contrast-enhanced 34
diameter 34
diffusion 34
dominant 34
DRG 34
enhancement 34
FLAIR 34
focal 34
glycolysis 34
hindered 34
hypoxia 34
images 34
invasiveness 34
mechanical 34
morphological 34
neoplastic 34
nodules 34
non-enhancing 34
peritumoral 34
processing 34
proximal 34
rCBV 34
restricted 34
ROI 34
sciatic 34
T1 34
thalami 34
ultrasound 34
VFW 34
volumes 34
ADI-PEG20 35
ASS1-deficient 35
BEP 35
carboplatin 35
CDDP 35
Cis 35
cisplatin 35
debulked 35
EP 35
ES-SCLC 35
etoposide 35
gemcitabine-based 35
optimally 35
pegylated 35
pemetrexed 35
regi 35
savolitinib 35
Tax 35
TRAP 35
vinorelbine 35
x4 35
dem 36
Even 36
mutant 36
PIK3CA-mutant 36
SAR 36
benchmarks 37
bias 37
CBS 37
IT 37
OS-derived 37
precise 37
RCTs 37
scoring 37
surrogate 37
surrogates 37
tendency 37
unavailable 37
unbiased 37
agonist 38
agonistic 38
antibody 38
B7 38
binding 38
binds 38
bispecific 38
blocks 38
cally 38
CD47 38
CD80 38
conjugated 38
construct 38
Durvalumab 38
engaging 38
FGFR2b 38
FPA144 38
GS-5745 38
high-affinity 38
human 38
humanized 38
IgG1 38
IgG4 38
investigational 38
linker 38
Ltd 38
mAb 38
MedImmune 38
microtubule 38
monoclonal 38
PF-8600 38
recombinant 38
TCB 38
toxin 38
18.3% 39
1991 39
31.2% 39
55.7% 39
688 39
80.6% 39
Age 39
AIDS-KS 39
CCNU 39
CKS 39
HRC 39
interquartile 39
IQR 39
osarc 39
percentile 39
Potential 39
RAO 39
SO 39
SP 39
Variable 39
Variation 39
worse 39
CIM 40
GPS 40
High 40
Intermediate 40
Low 40
PCD 40
Risk 40
SDs 40
std 40
administering 41
anti-diabetic 41
antiemetic 41
apixaban 41
APR 41
aprepitant 41
breakthrough 41
CINV 41
delayed 41
delays 41
emetogenic 41
fosaprepitant 41
GEN-1 41
GRAN 41
HEC 41
HIT 41
nail 41
NEPA 41
onycholysis 41
pegfilgrastim 41
prescribed 41
receiving 41
serotonin 41
solution 41
suffer 41
TP 41
consisted 42
HFSRT 42
histologically-confirmed 42
IIIb 42
IIIB 42
IIIB-IV 42
IIIC 42
IV 42
Q2W 42
stage 42
BSI 43
loss 43
lost 43
obser 43
observe 43
PCWG 43
Pro 43
skeletal 43
SMI 43
time 43
units 43
vation 43
background 44
bound 44
explained 44
identical 44
labelled 44
living 44
moderate 44
mor 44
normal 44
perform 44
populations 44
rapid 44
rapidly 44
returned 44
space 44
summary 44
104 45
111 45
136 45
144 45
190 45
191 45
202 45
234 45
263 45
272 45
307 45
389 45
426 45
433 45
473 45
486 45
555 45
573 45
579 45
827 45
Correlation 45
Typical 45
affordability 46
agencies 46
agency 46
assumptions 46
billing 46
capita 46
CAV 46
choosing 46
comparator 46
competition 46
costly 46
Countries 46
country 46
Decision 46
drug 46
drugs 46
economic 46
ensuring 46
ESMO 46
ESMO-MCBS 46
framework 46
frameworks 46
funding 46
HAS 46
hematology 46
industry 46
investment 46
launch 46
MACRA 46
Magnitude 46
manufacturers 46
market 46
measure 46
mix 46
NICE 46
oncology 46
pay 46
payer 46
payments 46
pCODR 46
prescribing 46
price 46
prices 46
pricing 46
problematic 46
rating 46
recommendation 46
reimbursement 46
reliability 46
reporting 46
Review 46
Top 46
transparency 46
validity 46
valuation 46
VFs 46
vial 46
wastage 46
WG 46
1108 47
ATLANTIC 47
BREAK-3 47
CD73 47
CP1108 47
GE 47
LM2 47
LM 47
NCT01693562 47
NCT02087423 47
PD1 47
PDL1 47
UBC 47
11.1% 48
11.5% 48
13.6% 48
15.3% 48
16.6% 48
21.3% 48
22.2% 48
27.3% 48
29.5% 48
33.3% 48
35.5% 48
37.5% 48
40.9% 48
44.4% 48
45.0% 48
57.1% 48
63.9% 48
7.3% 48
Deaths 48
Unconfirmed 48
Archival 49
clone 49
cores 49
Dako 49
E1L3N 49
H-score 49
IHC 49
immunofluorescence 49
immunohisto 49
immunohistochemical 49
immunohistochemistry 49
ISH 49
Ki-67 49
microarrays 49
pathologist 49
pharmDx 49
quantitative 49
RT-PCR 49
scored 49
signed 49
situ 49
slides 49
SP142 49
SP263 49
specimens 49
stained 49
staining 49
suspension 49
TMAs 49
Ventana 49
VENTANA 49
weak 49
add 50
additional 50
conduct 50
equivalent 50
feasible 50
indication 50
permit 50
provided 50
result 50
return 50
stantial 50
unable 50
11.8 51
12.3 51
13.2 51
14.0 51
14.2 51
14.3 51
14.5 51
14.7 51
15.0 51
15.1 51
15.3 51
15.4 51
15.8 51
16.7 51
16.8 51
16.9 51
17.1 51
17.2 51
17.6 51
17.7 51
18.0 51
18.1 51
18.4 51
18.5 51
18.6 51
18.8 51
19.0 51
19.1 51
19.2 51
19.3 51
19.7 51
20.2 51
20.3 51
20.7 51
20.8 51
21.0 51
21.1 51
21.3 51
21.5 51
22.0 51
22.1 51
22.2 51
22.4 51
22.5 51
22.6 51
23.0 51
23.4 51
23.6 51
23.9 51
24.0 51
24.2 51
24.3 51
24.5 51
24.8 51
25.0 51
25.1 51
25.5 51
25.6 51
25.7 51
25.8 51
25.9 51
26.3 51
26.4 51
26.6 51
27.1 51
27.2 51
27.3 51
27.4 51
27.5 51
27.6 51
27.8 51
27.9 51
28.2 51
28.6 51
28.9 51
29.7 51
29.8 51
29.9 51
30.0 51
30.6 51
31.4 51
31.5 51
31.9 51
32.4 51
32.8 51
33.0 51
33.1 51
33.3 51
34.5 51
37.5 51
37.6 51
38.3 51
38.5 51
38.6 51
38.7 51
38.8 51
39.0 51
39.3 51
40.1 51
40.9 51
41.3 51
43.3 51
45.5 51
47.8 51
50.0 51
50.8 51
53.5 51
54.2 51
57.1 51
59.1 51
60.9 51
62.5 51
68.5 51
6.9 51
69.5 51
8.6 51
9.1 51
deceased 51
E5 51
MTT 51
NR 51
PFS1 51
Range 51
Reference 51
Unfavorable 51
305 52
Bevacizumab 52
mutation 52
RF 52
ACS 53
City 53
Cruz 53
Family 53
Foudation 53
Genetic 53
Huntsman 53
Inc 53
Initiative 53
Laboratories 53
Lake 53
Ovarian 53
Salt 53
Santa 53
unaffected 53
UT 53
Utah 53
ACRT 54
ACT 54
AJCC 54
arising 54
cT4 54
definitive 54
ECE 54
I-II 54
M0 54
M1a 54
MIBC 54
N0-1 54
N2 54
non-metastatic 54
NRT 54
operated 54
pathologically 54
PL 54
PORT 54
RC 54
rectal 54
resected 54
RSI 54
SACURA 54
SBM 54
staged 54
STR 54
SX 54
thoracic 54
UFT 54
Utilizing 54
wedge 54
adults 55
AL 55
Alabama 55
Birmingham 55
considered 55
fields 55
K 55
treatment-na 55
untreated 55
acral 56
Barr 56
Clinicopathologic 56
CUP 56
Histologic 56
Integrative 56
melanomas 56
Merkel 56
penile 56
TCs 56
TET 56
TETs 56
thymic 56
thymoma 56
viral 56
virus 56
conditioning 57
Total 57
ALC 58
ALK-positive 58
ALTA 58
Anlotinib 58
apatinib 58
BRG 58
crizotinib 58
CRZ 58
CRZ-resistant 58
domized 58
fruquintinib 58
pivotal 58
tivozanib 58
Totally 58
device 59
Each 59
Following 59
gross 59
monthly 59
post 59
Sample 59
sampling 59
Subjects 59
subsequently 59
undergo 59
underwent 59
A. 60
Alexander 60
Aurora 60
Ben 60
Bendell 60
Burris 60
C. 60
Cannon 60
Canter 60
D. 60
Frederick 60
H. 60
Herlev 60
Howard 60
Huang 60
I. 60
Institute 60
Jeffrey 60
Johnson 60
Laura 60
Lee 60
Melbourne 60
Moffitt 60
Nashville 60
Nicholas 60
Pittsburgh 60
PLLC 60
Portland 60
Providence 60
R. 60
Rebecca 60
Research 60
Sarah 60
Shah 60
Simultaneous 60
Steven 60
stitute 60
Taipei 60
Tampa 60
Tennessee 60
TN 60
Tufts 60
Vanderbilt 60
002 61
acupuncture 61
anxiety 61
au 61
autonomic 61
avoidant 61
coherence 61
coping 61
cramps 61
daytime 61
depression 61
depressive 61
distress 61
disturbances 61
drowsiness 61
dryness 61
dys 61
dysfunction 61
dyspareunia 61
HRV 61
Improvement 61
insomnia 61
interference 61
module 61
mood 61
OXN 61
pain 61
PHQ-9 61
posterior 61
post-HCT 61
PTSD 61
sexual 61
sleep 61
SMART-3RP 61
stress 61
symptoms 61
well-being 61
yoga 61
BCL2 62
BCL6 62
CD20 62
CD79B 62
COO 62
DH 62
DHL 62
GCB 62
hem 62
HGBL 62
hit 62
IGH 62
inferior 62
lym 62
MYC 62
non-GCB 62
Subtype 62
THL 62
AbbVie 63
acute 63
AHCT 63
ALL 63
Allogeneic 63
azacitidine 63
azacytidine 63
COG 63
CPX-351 63
cytarabine 63
elderly 63
Enasidenib 63
FLT3mut 63
frontline 63
gilteritinib 63
GMI-1271 63
hematopoietic 63
HR-MDS 63
induction 63
intensive 63
Jorge 63
leukemia 63
lymphoblastic 63
lymphocytic 63
MEC 63
mini-hyper-CVD 63
myelofibrosis 63
myeloid 63
ozogamicin 63
relapsed 63
stem 63
tAML 63
CMML 64
cytogenetic 64
cytogenetics 64
ELN 64
IPSS 64
karyotype 64
LGLL 64
lower-risk 64
Majority 64
MPAL 64
MPN 64
MPN-U 64
myelodysplastic 64
myeloproliferative 64
Ruxolitinib 64
Significance 64
SRSF2 64
trisomy 64
addition 65
affect 65
appears 65
balance 65
benefits 65
composite 65
compromising 65
conclude 65
conventional 65
decreases 65
delaying 65
earlier 65
extending 65
faster 65
improve 65
improved 65
improvement 65
improvements 65
improves 65
improving 65
interfere 65
managing 65
minimal 65
opposed 65
partially 65
provement 65
rdCRT 65
reduces 65
reducing 65
sdCRT 65
spite 65
tion 65
translate 65
VEN 65
Additionally 66
NT 66
RA 66
TAM 66
trans 66
1011 67
600 67
800 67
Ad 67
apheresis 67
CAR-Ts 67
co-administration 67
Cy 67
cyclophosphamide 67
Cyclophosphamide 67
dosed 67
Expansion 67
fludarabine 67
GANET 67
HD-MTX 67
HER2-CAR 67
hrs 67
infused 67
infusion 67
infusions 67
intradermal 67
intraperitoneally 67
IRN 67
LDC 67
lymphodepleting 67
lymphodepletion 67
MGD006 67
sc 67
Subsequent 67
VCR 67
x106 67
cohort 68
cohorts 68
120 69
ACM 69
combined 69
favourable 69
HDT 69
intensification 69
mL 69
versus 69
CB 70
interaction 70
maintenance 70
Diagnosis 71
Factors 71
lymphedema 71
MRM 71
Multiple 71
Organ 71
Single 71
Unk 71
Adaptive 72
Alliance 72
Fred 72
Hutchinson 72
Seattle 72
WA 72
Washington 72
0.0016 73
1% 73
24.1% 73
CPS 73
IC2 73
IFNG 73
KL 73
LAG3 73
LUAC 73
MCPyV 73
mi 73
mMCC 73
NQO1 73
PD-L1 73
PD-L2 73
positivity 73
TC0 73
TC1 73
TIM3 73
TPS 73
tumor-infiltrating 73
challenges 74
chance 74
child 74
choose 74
clarify 74
contemporary 74
contributed 74
contributes 74
disparities 74
disparity 74
dissemination 74
dramatically 74
ence 74
epidemiologic 74
ethnic 74
Few 74
Future 74
goal 74
guideline 74
HRT 74
inappropriate 74
justify 74
largest 74
LCH 74
Little 74
minorities 74
persist 74
persists 74
PIM 74
polypharmacy 74
pre-existing 74
racial 74
trends 74
understand 74
understanding 74
Understanding 74
understudied 74
uniquely 74
utilization 74
AAs 75
activation 75
Pembro 75
presentation 75
GCR 76
XO 76
blast 77
BMBL 77
cGVHD 77
dependence 77
hematologic 77
incomplete 77
independence 77
JAKi 77
MF 77
MMB 77
MRD-neg 77
RBC 77
reaching 77
recovery 77
relief 77
remission 77
requirement 77
RUX 77
spleen 77
TD 77
TI 77
transfusion 77
TSS 77
18 78
frequency 78
N 78
PET 78
compare 79
compared 79
comparing 79
Comparing 79
comparison 79
control 79
icant 79
long-term 79
ment 79
multi-agent 79
NCT 79
Plerixafor 79
RTOG 79
Sema4D 79
short 79
short-term 79
superior 79
terms 79
apies 80
Combination 80
CPI 80
dense 80
failing 80
finding 80
inhibitors 80
merits 80
monotherapy 80
More 80
mTNBC 80
respond 80
responsive 80
ther 80
TNBC 80
triple 80
unselected 80
amol 81
Asia 81
CLDN18 81
criterion 81
Europe 81
FAST 81
GEJ 81
Main 81
MS 81
rest 81
sites 81
tained 81
TUBB3 81
63.6% 82
cluded 82
confirmed 82
died 82
dis 82
disease 82
EGFRmutations 82
Eight 82
Eleven 82
exhibiting 82
Fifteen 82
firmed 82
Five 82
For 82
Four 82
injectable 82
munotherapy 82
Nine 82
Nineteen 82
Of 82
One 82
Only 82
patients 82
POD 82
progressions 82
pt 82
refused 82
responded 82
Seven 82
Seventeen 82
Six 82
Sixty 82
subject 82
Ten 82
There 82
Thirteen 82
Three 82
treated 82
Twenty 82
Twenty-four 82
Two 82
analysed 83
archival 83
Available 83
bi 83
biomarkers 83
blood-based 83
cir 83
col 83
collected 83
digital 83
Digital 83
droplet 83
dynamics 83
InVision 83
lected 83
monitor 83
PCR 83
personalised 83
Plasma 83
quantification 83
quencing 83
se 83
sequence 83
serial 83
Serial 83
stored 83
substudies 83
tagged-amplicon 83
tection 83
Translational 83
turnaround 83
Amp 84
ceiving 84
LSS 84
MVA 84
NS 84
PH 84
pre-RT 84
Receipt 84
SH 84
S-1 85
TAS-118 85
Y90 85
carrying 86
D842V 86
GIST 86
GISTs 86
imatinib 86
Imatinib 86
KIT 86
LTB 86
mitosis 86
mitotic 86
PDGFRa 86
PDGFRA 86
STB 86
Bendamustine 87
bortez 87
bortezomib 87
carfilzomib 87
Carfilzomib 87
CASTOR 87
DARA 87
daratumumab 87
Daratumumab 87
DCT 87
dex 87
Dex 87
DEX 87
dexamethasone 87
DURVA 87
elo 87
elotuzumab 87
IMiD 87
IMiDs 87
ISA 87
ixazomib 87
Ixz 87
len 87
Len 87
LEN 87
lenalidomide 87
Lenalidomide 87
LoDEX 87
LOT 87
low-dose 87
melphalan 87
mens 87
MOR202 87
POLLUX 87
Pom 87
POM 87
pomalidomide 87
Pomalidomide 87
proteasome 87
RRMM 87
up-front 87
active 88
HD-CTx 88
incurable 88
option 88
reasonable 88
replacement 88
Trabectedin 88
CLIPT 89
comprised 89
deliver 89
mended 89
modified 89
recom 89
utilizes 89
adapted 90
assessment 90
based 90
Committee 90
Continuous 90
defined 90
determination 90
determined 90
determining 90
discretion 90
employing 90
estimation 90
extra 90
interventional 90
investigators 90
omitting 90
pathology 90
prohibitive 90
protocol 90
repeated 90
requires 90
revised 90
sessments 90
system 90
verify 90
enrollment 91
patient 91
persistent 91
ten 91
To 91
adequate 92
Child-Pugh 92
criteria 92
dimension 92
documented 92
ECOG 92
eli 92
eligibility 92
Eligibility 92
eligible 92
Eligible 92
entry 92
excluded 92
exclusion 92
Exclusion 92
expectancy 92
formance 92
inclusion 92
ineligible 92
Key 92
measurable 92
organ 92
performance 92
prior 92
Prior 92
PS 92
Pts 92
systemic 92
Zubrod 92
DC 93
Rapid 93
Au 94
cance 94
Cance 94
ce 94
Cen 94
da 94
gpNMB 94
ina 94
io 94
irst 94
iversity 94
lly 94
logy 94
ma 94
maint 94
Med 94
Pa 94
ra 94
Resistance 94
rs 94
ta 94
tas 94
te 94
tes 94
tho 94
toma 94
ton 94
tu 94
tumo 94
ty 94
Un 94
Univers 94
1006 95
First-line 95
lus 95
ly 95
lyses 95
op 95
Affymetrix 96
Agilent 96
array 96
Array 96
arrays 96
assay 96
Assay 96
assayed 96
assays 96
Bank 96
CLIA-certified 96
custom 96
EGFRa 96
extracted 96
FFPE 96
formalin-fixed 96
formed 96
genotyping 96
Illumina 96
kit 96
Kit 96
libraries 96
library 96
ligation 96
METa 96
microarray 96
multiplex 96
multiplexed 96
nCounter 96
paraffin-embedded 96
performed 96
processed 96
proximity 96
qRT-PCR 96
quantitated 96
quantitation 96
reverse 96
RNA 96
RNAseq 96
RNA-Seq 96
RPPA 96
samples 96
Samples 96
sections 96
subjected 96
Subsequently 96
synthesized 96
Technologies 96
transcriptome 96
tubes 96
X 96
ACMG 97
additionally 97
AIA 97
allelic 97
analyzing 97
autosomal 97
benign 97
bioinformatic 97
CACI 97
chromosomal 97
chromosome 97
classify 97
counting 97
ExAC 97
gains 97
genome-wide 97
heritable 97
iden 97
identifiable 97
imbalance 97
interrogated 97
locus 97
losses 97
meningioma 97
MLKL 97
necroptosis 97
notable 97
overlap 97
PathoMAN 97
penetrance 97
prevalence 97
priori 97
screen 97
sions 97
SNP 97
striking 97
tified 97
tions 97
underlying 97
variation 97
variations 97
CETUX 98
FECD 98
Oxa 98
post-hoc 98
RDI 98
See 98
subgroup 98
subgroups 98
table 98
Table 98
yo 98
DF 99
HSCT 99
MOD 99
multi-organ 99
obstruction 99
onset 99
post-diagnosis 99
post-HSCT 99
SOS 99
transplantation 99
VOD 99
ICI 100
IRAEs 100
IU 100
pelvis 100
PNS 100
Ta 100
TRT 100
U 100
1.1 101
censored 101
declared 101
DoR 101
DOR 101
duration 101
Enrolled 101
FD 101
ICR 101
IRF 101
lock 101
mo 101
P2 101
per-protocol 101
PFS2 101
reached 101
Responses 101
summarized 101
AMI 102
CAD 102
cardiotoxicity 102
CHF 102
cidence 102
coronary 102
creased 102
creasing 102
CVA 102
CVD 102
dementia 102
Diabetes 102
Discharge 102
dying 102
fa 102
heart 102
increased 102
Increased 102
infarction 102
intense 102
life-threatening 102
myocardial 102
NCP 102
new-onset 102
non-statistically 102
person-years 102
premature 102
prevalent 102
preventive 102
radiation-induced 102
slight 102
SMN 102
special 102
stroke 102
Survivors 102
BRAFV600E 103
MBM 103
PD1i 103
re-challenge 103
Tx 103
anti-cancer 104
2005 105
2007 105
2008 105
2009 105
2011 105
2012 105
2013 105
2014 105
2015 105
al 105
Clin 105
Engl 105
J 105
JAMA 105
JCO 105
Lancet 105
mPC 105
NEJM 105
Onc 105
Oncol 105
representing 105
Res 105
Sci 105
Transl 105
ALK 106
c-Met 106
c-MET 106
CN 106
METdel14 106
NSCLC 106
rearrangement 106
ROS1 106
TKI 106
TKIs 106
viously 106
Adams 107
Alexandra 107
Andrew 107
Ann 107
Arbor 107
Buffalo 107
cancer 107
Charles 107
Charlotte 107
Daniel 107
Del 107
Detroit 107
Edward 107
Enrique 107
F. 107
Feinberg 107
Gary 107
George 107
Hospitals 107
Icahn 107
IL 107
J. 107
Jean 107
Jeremy 107
John 107
Joseph 107
Joshua 107
K. 107
Leuven 107
Lisa 107
Louis 107
Lurie 107
Mark 107
Matthew 107
Medicine 107
MI 107
Michael 107
Michigan 107
Miller 107
Mount 107
N. 107
Northwestern 107
O. 107
Oakland 107
Park 107
Peter 107
Philip 107
Pritzker 107
QC 107
Rachel 107
Robert 107
Roswell 107
Ryan 107
Samuel 107
Sandra 107
School 107
Sinai 107
Smith 107
Therapeutic 107
Tom 107
Tucson 107
Victoria 107
Virginia 107
Wayne 107
West 107
William 107
Y. 107
Yang 107
CCT 108
computed 108
computer 108
CXR 108
emission 108
FDG-PET 108
imaging 108
PET-CT 108
positron 108
surveillance 108
tomography 108
waiting 108
2500 109
634 109
ACE 109
amplicon 109
annotated 109
base 109
bp 109
calls 109
capture-based 109
Caris 109
classes 109
CLIA 109
CNA 109
CNAs 109
CNV 109
coding 109
copy 109
Copy 109
deletions 109
detects 109
exome 109
Exome 109
exons 109
Expanded 109
FoundationACT 109
FoundationOne 109
gDNA 109
genes 109
genome 109
genomes 109
Genome-wide 109
Guardant360 109
hotspot 109
hybrid 109
hybrid-capture 109
indels 109
insertion 109
insertions 109
internal 109
interrogation 109
introns 109
lab 109
mapped 109
match 109
Matched 109
MSK-IMPACT 109
next-generation 109
NGS 109
NGS-based 109
nucleotide 109
Oncomine 109
pair 109
pathogenicity 109
pipeline 109
PMID 109
profiled 109
quenced 109
reads 109
rearranged 109
regions 109
saliva 109
sequencing 109
single-nucleotide 109
SNV 109
substitutions 109
twenty 109
WES 109
WGS 109
whole-exome 109
angiosarcoma 110
a-SHH 110
dedifferentiated 110
desmoplastic 110
epithelioid 110
ES 110
Ewing 110
gastro-intestinal 110
leiomyosarcoma 110
liposarcoma 110
LMS 110
MRCL 110
myxoid 110
osteosarcoma 110
pleomorphic 110
p-SHH 110
rhabdomyosarcoma 110
round 110
sarcomas 110
SHH 110
SS 110
STS 110
synovial 110
SyS 110
ten-year 110
UPS 110
associates 111
bacteria 111
Characterization 111
composition 111
diversity 111
eQTLs 111
explain 111
extensively 111
gut 111
ICB 111
immune 111
INFG 111
integration 111
landscapes 111
melanoma 111
microbiome 111
microbiota 111
MMR-D 111
neoantigen 111
neoantigens 111
NM 111
PRKDC 111
spreading 111
SSM 111
ANG-2 112
angiogenesis 112
angiogenic 112
endoglin 112
endothelial 112
ligands 112
OPN 112
receptors 112
signal 112
soluble 112
TGFb 112
TGFbR3 112
Tie2 112
TRC105 112
VAN 112
vascular 112
Vascular 112
vasculature 112
VEGF 112
VEGF-A 112
VEGFi 112
Haven 113
highly 113
Immune 113
repertoire 113
Yale 113
1973 114
End 114
Epidemiology 114
registries 114
SEER 114
Surveillance 114
B. 115
Biomarkers 115
circulating 115
Circulating 115
hoc 115
L. 115
nomograms 115
Outcomes 115
predict 115
BSC 116
DpR 116
ETS 116
IS 116
mOS 116
mPFS 116
pmab 116
1994 117
1997 117
2001 117
2003 117
2010 117
agnosed 117
agnosis 117
consecutive 117
consecutively 117
di 117
institution 117
IRB 117
retrospectively 117
reviewed 117
Selected 117
stitution 117
undergone 117
ASPIRE 118
BM 118
IRE 118
delay 119
DT 119
switch 119
TR 119
asbestos 120
ASS1 120
environmental 120
malignant 120
Malignant 120
mesothelioma 120
MPM 120
pleural 120
Systemic 120
latency 121
NNS 121
NPLC 121
Observed 121
separated 121
SIR 121
XRT 121
157 122
192 122
193 122
194 122
210 122
211 122
212 122
216 122
217 122
226 122
229 122
235 122
236 122
237 122
239 122
243 122
244 122
249 122
253 122
254 122
255 122
257 122
258 122
259 122
262 122
266 122
273 122
283 122
30 122
328 122
336 122
442 122
537 122
539 122
546 122
8 122
Genitourinary 122
Noncolorectal 122
Nonprostate 122
Whole 122
ADHD 123
analgesic 123
attention 123
BDI 123
behavior 123
behavioral 123
behaviors 123
CBM 123
cg 123
CHC 123
CIPN 123
cognitive 123
condition 123
connectivity 123
CRCI 123
deficit 123
deficits 123
emotional 123
functioning 123
geriatric 123
hearing 123
Hearing 123
impair 123
impairment 123
impairments 123
intellectual 123
Interventions 123
loneliness 123
MCS 123
physical 123
psychological 123
self-reported 123
SIPAT 123
SNHL 123
social 123
task 123
verbal 123
visual 123
Vitality 123
YAC 123
bone 124
exception 124
hema 124
joint 124
marrow 124
matter 124
sheath 124
sources 124
TGCT 124
pa 125
tients 125
VKORC1 125
authors 126
disclosure 126
list 126
search 126
Visit 126
122 127
149 127
152 127
178 127
92 127
96 127
alive 128
craniotomy 128
derwent 128
dFLC 128
diagnosis 128
Eighty 128
EPI-TAX 128
follow 128
follow-up 128
followup 128
Forty-six 128
labs 128
Missing 128
percent 128
Radiological 128
Re 128
seminoma 128
survived 128
Their 128
transplanted 128
UCLA 128
With 128
sensitivity 129
specificity 129
Abemaciclib 130
AI 130
AIs 130
alpelisib 130
anastrozole 130
anthracyclines 130
anti-estrogen 130
anti-HER2 130
aromatase 130
AZD4547 130
CDK 130
CDK4 130
CLEOPATRA 130
cyclin-dependent 130
EBC 130
emtansine 130
endocrine 130
ER-positive 130
estradiol 130
estrogen 130
EV 130
FUL 130
fulvestrant 130
HER22 130
HER2-negative 130
HER2-positive 130
hormone 130
Hormone 130
HP 130
ineffective 130
Jose 130
later-line 130
letrozole 130
mBC 130
MBCP 130
neo 130
node-positive 130
palbociclib 130
pertuzumab 130
PHEREXA 130
post-menopausal 130
postmenopausal 130
premenopausal 130
RAD1901 130
receptor-positive 130
ribociclib 130
Sevi 130
SOLE 130
TAK-228 130
tamoxifen 130
Tamoxifen 130
taselisib 130
taxane-based 130
T-DM1 130
trastuzumab 130
Trastuzumab 130
tuzumab 130
Tz 130
ultimate 130
150 131
200 131
240 131
250 131
300 131
400 131
480 131
500 131
960 131
bid 131
BID 131
break 131
CC-486 131
continuously 131
daily 131
exceeded 131
intolerable 131
MoCA 131
permitted 131
PO 131
Q3W 131
qd 131
unacceptable 131
vismodegib 131
0.049 132
basal-like 132
BCBM 132
BCs 132
ENT 132
ER 132
HER1 132
HER 132
Her2 132
HER2 132
HER2-targeted 132
I-SPY 132
Ki67 132
LN 132
Lum 132
luminal 132
Luminal 132
MCF7 132
METABRIC 132
p-4EBP1 132
p-Akt 132
p-AR 132
PgR 132
progesterone 132
Rb 132
sTILs 132
triple-negative 132
trop2e 132
Trop2e 132
Wnt5a 132
dx 133
HRHPV 133
individuals 133
infection 133
meet 133
calculator 134
CIN 134
FN 134
guidelines 134
Hosmer 134
If 134
LP 134
missed 134
NCCN 134
recommend 134
Severe 134
sta 134
0.99 135
1.01 135
1.02 135
1.03 135
1.04 135
1.05 135
1.06 135
1.07 135
1.08 135
1.09 135
1.10 135
1.11 135
1.12 135
1.13 135
1.14 135
1.15 135
1.16 135
1.17 135
1.18 135
1.19 135
1.20 135
1.21 135
1.22 135
1.23 135
1.24 135
1.25 135
1.26 135
1.27 135
1.28 135
1.29 135
1.30 135
1.31 135
1.32 135
1.33 135
1.34 135
1.35 135
1.36 135
1.37 135
1.38 135
1.39 135
1.40 135
1.41 135
1.42 135
1.43 135
1.44 135
1.45 135
1.46 135
1.47 135
1.48 135
1.49 135
1.50 135
1.51 135
1.52 135
1.53 135
1.54 135
1.55 135
1.56 135
1.57 135
1.58 135
1.59 135
1.60 135
1.61 135
1.62 135
1.63 135
1.64 135
1.65 135
1.66 135
1.67 135
1.68 135
1.69 135
1.70 135
1.71 135
1.72 135
1.73 135
1.74 135
1.75 135
1.77 135
1.78 135
1.79 135
1.82 135
1.83 135
1.84 135
1.85 135
1.86 135
1.87 135
1.88 135
1.89 135
1.90 135
1.91 135
1.92 135
1.93 135
1.95 135
1.96 135
1.97 135
2.01 135
2.02 135
2.04 135
2.06 135
2.10 135
2.12 135
2.13 135
2.14 135
2.15 135
2.16 135
2.17 135
2.18 135
2.20 135
2.23 135
2.24 135
2.30 135
2.31 135
2.32 135
2.34 135
2.35 135
2.39 135
2.41 135
2.42 135
2.47 135
2.50 135
2.55 135
2.57 135
2.67 135
2.70 135
2.75 135
2.79 135
2.80 135
2.85 135
2.88 135
2.91 135
2.92 135
2.93 135
2.96 135
3.00 135
3.12 135
3.26 135
3.35 135
3.42 135
3.68 135
aHR 135
AHR 135
aOR 135
aRR 135
BCR-free 135
cancer-free 135
CAPOX 135
Confidence 135
die 135
Interval 135
spread 136
0630 137
80.8% 137
9514 137
Cape 137
CapOx 137
CF 137
C-RT 137
CTRT 137
downstaging 137
DP 137
ECF 137
ECX 137
EFS 137
EG 137
EN 137
ETW 137
favored 137
finished 137
five-year 137
gastrectomy 137
G-high 137
incidences 137
laparoscopic 137
LE 137
OAW 137
Obs 137
PCI 137
RAP 137
recurrences 137
sBM 137
stomach-preserving 137
VP 137
yDFS 137
005 138
baseline 138
C30 138
Compliance 138
deterioration 138
EORTC 138
EQ-5D 138
EQ-5D-3L 138
FACT-B 138
FBT 138
GHS 138
HRQoL 138
HRQOL 138
Improved 138
Intervention 138
KRG 138
life 138
maintained 138
MWT 138
opioid 138
PedsQL 138
post-chemotherapy 138
PRO-CTCAE 138
PVT 138
QLQ 138
QLQ-C30 138
QoL 138
QOL 138
quality 138
questionnaire 138
questionnaires 138
Questionnaires 138
satisfaction 138
scores 138
Statistically 138
subscales 138
terioration 138
TMT 138
TOI 138
VAS 138
Week 138
X2 138
YCE 138
Yoga 138
12% 139
14% 139
16% 139
21% 139
24% 139
27% 139
28% 139
31% 139
34% 139
37% 139
38% 139
40% 139
41% 139
47% 139
59% 139
6% 139
7% 139
8% 139
biosimilar 140
Company 140
Consensus 140
Eli 140
exposure-response 140
Funding 140
Genentech 140
icalTrials 140
Lilly 140
Pfizer 140
Roche 140
Sanofi 140
Sponsor 140
Support 140
supported 140
Supported 140
U10CA180821 140
U10CA180882 140
aCT 141
adjustment 141
bining 141
biologic 141
candidates 141
cate 141
clinicopathological 141
confers 141
CTC-status 141
DAC 141
DMA 141
DOT 141
existed 141
factors 141
favorable 141
Heng 141
In 141
independent 141
independently 141
insignificant 141
irrespective 141
MVD 141
nificant 141
nostic 141
pharmacogenomic 141
PM-IPI 141
poorer 141
post-OP 141
predictive 141
predictor 141
predictors 141
predicts 141
prog 141
prognostic 141
sig 141
split 141
static 141
status 141
strata 141
stratification 141
stratify 141
strongest 141
SU 141
tivariate 141
unfavorable 141
unfit 141
abundance 142
bx 142
Bx 142
infiltration 142
marker 142
markers 142
nx 142
paired 142
PDL-1 142
post-treatment 142
pretreatment 142
spatial 142
subsets 142
TCI 142
t-test 142
tumor 142
tumoral 142
anti-EGFR 144
anti-VEGF 144
B-701 144
cetuximab 144
Cetuximab 144
combo 144
CTx 144
doc 144
mono 144
ph 144
SA 144
sun 144
171 145
functional 145
predicting 145
15 146
352 146
361 146
363 146
364 146
365 146
366 146
367 146
368 146
371 146
398 146
423 146
45 146
AM-9 146
Care 146
Cost-effectiveness 146
Disparities 146
Do 146
Does 146
Evaluating 146
Gynecologic 146
Impact 146
Informatics 146
PM-2 146
PM-4 146
Quality 146
Science 146
Services 146
Symposium 146
0.5 147
0.8 147
controls 147
Dx 147
attributable 148
chronic 148
conditions 148
experi 148
mental 148
visits 148
180 149
adult 149
consists 149
DPYD 149
ducted 149
Herein 149
selected 149
total 149
x2 149
assessed 150
assessments 150
BICR 150
blinded 150
central 150
INV 150
investigator 150
Neuro-Oncology 150
Planned 150
Q12W 150
Q6W 150
Q9W 150
radiologic 150
radiology 150
RECIST 150
review 150
Solid 150
v1 150
vendor 150
contrast 151
enhancing 151
MRI 151
0.0004 152
0.0008 152
0.001 152
0.0019 152
0.003 152
0.004 152
0.005 152
0.006 152
0.007 152
0.008 152
0.009 152
0.01 152
0.015 152
0.016 152
0.017 152
0.020 152
0.02 152
0.022 152
0.023 152
0.024 152
0.026 152
0.029 152
0.030 152
0.031 152
0.03 152
0.032 152
0.033 152
0.035 152
0.043 152
0.045 152
0.047 152
0.055 152
0.056 152
36.9% 152
62.5% 152
93.9% 152
asso 152
ciated 152
counterparts 152
CUI 152
duced 152
Higher 152
lower 152
Lower 152
nificantly 152
non-white 152
persisted 152
shorter 152
Significantly 152
stringent 152
TABLE 152
Though 152
VI 152
b-cell 153
B-cell 153
BCL 153
BEN 153
bendamustine 153
BTKi 153
CLL 153
copanlisib 153
Copanlisib 153
diffuse 153
DLBCL 153
double-refractory 153
FL 153
follicular 153
fungoides 153
HL 153
Hodgkin 153
INCB050465 153
Locke 153
LPL 153
lymphoma 153
lymphomas 153
mantle 153
marginal 153
MCL 153
Milwaukee 153
MOR208 153
mycosis 153
MZL 153
nancies 153
NHL 153
non-Hodgkin 153
PI3Kd 153
PTCL 153
rel 153
Relapsed 153
Richter 153
R-R 153
SLL 153
transformation 153
transformed 153
WI 153
WM 153
zone 153
Cohort 154
crucial 154
implies 154
inform 154
insufficient 154
obtaining 154
wider 154
accepted 155
aging 155
Beva 155
car 155
decade 155
difficult 155
distinguishing 155
eliminate 155
entity 155
exist 155
extrapolated 155
fit 155
focus 155
focusing 155
form 155
highlight 155
includes 155
incorporation 155
indicator 155
ities 155
Its 155
large-scale 155
MMMT-O 155
optimize 155
powerful 155
purpose 155
reflects 155
selecting 155
sizable 155
sought 155
termine 155
traditional 155
varies 155
ventional 155
well-defined 155
Whether 155
cancer-related 156
carried 156
certified 156
ESBC 156
Genomics 156
nationwide 156
NCORP 156
offered 156
participate 156
participated 156
Physicians 156
Screening 156
Se 156
UR 156
URCC 156
view 156
atypical 157
mts 157
RAS 157
typical 157
WT 157
admission 158
antidepressant 158
avoidable 158
code 158
consultation 158
department 158
DNR 158
emergency 158
end-of 158
end-of-life 158
FIM 158
hos 158
hospital 158
hospitalization 158
hospitalizations 158
hospitalized 158
ICU 158
Increase 158
incurred 158
inpatient 158
Inpatient 158
IPCR 158
LOS 158
LWC 158
medication 158
metric 158
non-curative 158
Palliative 158
Patient 158
Physician 158
Pp 158
PpChronic 158
rehabilitation 158
service 158
source 158
specialized 158
SPPC 158
Supportive 158
surveys 158
terminal 158
timeliness 158
timing 158
trajectory 158
transitions 158
Trends 158
admissions 159
admitted 159
adversely 159
agitated 159
burden 159
CCD 159
delirium 159
high-intensity 159
ICS 159
Increasing 159
indicators 159
length 159
morbidity 159
NET 159
non-persistence 159
Patient-reported 159
PCS 159
psychiatric 159
stay 159
symptom 159
TCS 159
weekend 159
access 160
adoption 160
advocacy 160
assisted 160
attitudes 160
biospecimen 160
Brazilian 160
clinicians 160
clinics 160
cologists 160
commercial 160
community 160
community-based 160
cover 160
efforts 160
Electronic 160
focused 160
forward 160
gaps 160
GCI 160
implement 160
incorporate 160
initiative 160
Integrating 160
LMICs 160
medically 160
Minnesota 160
MTBs 160
multidisciplinary 160
munity 160
navigation 160
OCS 160
oncologic 160
organized 160
practices 160
professionals 160
program 160
programs 160
project 160
properly 160
purposes 160
QI 160
resource 160
scenario 160
scheduling 160
seek 160
seeking 160
settings 160
shortage 160
specialty 160
systematically 160
team 160
teams 160
technologies 160
technology 160
telephone 160
terventions 160
timely 160
urban 160
Utilization 160
utilize 160
views 160
worldwide 160
analyse 161
annually 161
CS 161
exam 161
examination 161
Improvements 161
Included 161
Modified 161
MRIs 161
participants 161
participating 161
pre-operative 161
spectroscopy 161
subclinical 161
subjective 161
sur 161
techniques 161
1989 162
1990 162
1995 162
1996 162
1998 162
1999 162
2000 162
2002 162
2006 162
534 162
732 162
965 162
abstracted 162
administrative 162
affiliated 162
attending 162
Australian 162
British 162
Centers 162
claim 162
claims 162
CMT 162
coded 162
codes 162
co-morbidities 162
database 162
databases 162
Death 162
electronic 162
FFS 162
filled 162
FMF 162
Healthcare 162
ICD-9 162
I-IV 162
Individuals 162
Information 162
linkage 162
LIVESTRONG 162
Mammography 162
mographic 162
mographics 162
national 162
NHIS 162
non-cancer 162
Norway 162
osteoporotic 162
Permanente 162
Planning 162
population-based 162
Private 162
Providers 162
record 162
records 162
Records 162
registry 162
Registry 162
representative 162
retrieved 162
SEER-Medicare 162
sociodemographic 162
Standardized 162
supplemental 162
veterans 162
AC2013 163
amplified 163
CAP 163
equivocal 163
FISH 163
HER-2 163
HER2-equivocal 163
hybridization 163
IHC2 163
IHC3 163
negative 163
reflex 163
Testing 163
unmatched 163
acizumab 164
allocated 164
Approximately 164
apy 164
assigned 164
che 164
chemother 164
chemotherapies 164
chemotherapy 164
definitively 164
doublet 164
front-line 164
GCIG 164
Maintenance 164
motherapy 164
ndline 164
NHB 164
nintedanib 164
niraparib 164
NOVA 164
Plat 164
platinum 164
platinum-based 164
Platinum-based 164
platinums 164
Randomization 164
Regimens 164
rucaparib 164
Standard 164
standard-of-care 164
topotecan 164
112 165
AC 165
decreasing 165
dependent 165
Neoadjuvant 165
Across 166
ADC 166
composed 166
expressed 166
glio 166
slow 166
CABA 167
examined 167
rechallenge 167
adjuvant 168
Adjuvant 168
BCSM 168
CALOR 168
Chemotherapy 168
conservation 168
CTC-positive 168
excised 168
hormone-receptor 168
ILRR 168
invasive 168
locoregional 168
margins 168
Mastectomy 168
PlanB 168
pN 168
recurrence 168
Recurrence 168
RS 168
Score 168
TAILORx 168
width 168
WSG 168
AGO 169
AGO-OVAR 169
Albert 169
Andre 169
Andrea 169
ao 169
Basel 169
Belgium 169
Berlin 169
Brazil 169
Brussels 169
Can 169
Copenhagen 169
Da 169
De 169
Denmark 169
ENGOT 169
Florence 169
Garcia 169
Gastroenterology 169
Hos 169
Lausanne 169
Maria 169
Martin 169
MMMT-E 169
multicentric 169
NSGO 169
Paulo 169
Raza 169
Rome 169
Switzerland 169
Universit 169
Universitaire 169
Van 169
well-established 169
Absolute 170
AR-Vs 170
BENIGNG 170
BL 170
d10 170
ddPCR 170
detectable 170
Detectable 170
DTX 170
exoNA 170
fall 170
HEALTHG 170
integrity 170
MAF 170
meEGFR-CTCs 170
mGSTP1 170
OECG 170
post-RT 170
post-surgical 170
preC3 170
Residual 170
TR0 170
TTPP 170
undetectable 170
VAF 170
232 171
289 171
290 171
293 171
342 171
358 171
373 171
374 171
378 171
380 171
381 171
382 171
383 171
385 171
386 171
387 171
388 171
390 171
396 171
399 171
402 171
417 171
430 171
548 171
822 171
Allotransplant 171
Chronic 171
Dyscrasia 171
Hematologic 171
Leukemia 171
Lymphocytic 171
Lymphoma 171
Malignancies 171
Myelodysplastic 171
Natural 171
Syndromes 171
Telomere 171
0 172
10 172
11 172
1 172
12 172
13 172
14 172
16 172
17 172
- 172
19 172
20 172
21 172
2 172
22 172
23 172
24 172
25 172
28 172
29 172
3 172
4 172
5 172
6 172
7 172
9 172
received 172
0.0% 173
0.9% 173
10.0% 173
10.3% 173
10.5% 173
10.8% 173
10.9% 173
1.1% 173
11.2% 173
11.3% 173
11.4% 173
12.1% 173
12.3% 173
12.7% 173
12.8% 173
13.2% 173
13.3% 173
13.7% 173
13.8% 173
14.1% 173
14.2% 173
14.3% 173
14.4% 173
14.6% 173
14.7% 173
14.8% 173
15.1% 173
15.2% 173
15.9% 173
16.3% 173
16.7% 173
1.7% 173
17.3% 173
17.4% 173
17.5% 173
17.7% 173
1.8% 173
18.8% 173
19.1% 173
2.1% 173
21.2% 173
21.7% 173
2.2% 173
22.4% 173
22.7% 173
24.3% 173
2.5% 173
25.9% 173
26.2% 173
2.7% 173
27.7% 173
27.9% 173
2.8% 173
28.3% 173
2.9% 173
3.0% 173
30.8% 173
31.3% 173
31.7% 173
3.2% 173
32.4% 173
32.7% 173
3.3% 173
34.1% 173
35.2% 173
3.7% 173
3.9% 173
4.0% 173
4.1% 173
4.2% 173
4.3% 173
4.5% 173
4.6% 173
46.2% 173
4.7% 173
4.8% 173
50.0% 173
5.1% 173
5.2% 173
5.3% 173
53.3% 173
53.5% 173
5.4% 173
5.5% 173
5.6% 173
57.7% 173
5.8% 173
58.8% 173
6.0% 173
6.1% 173
6.3% 173
6.4% 173
6.6% 173
6.7% 173
6.9% 173
7.0% 173
7.1% 173
7.5% 173
7.9% 173
8.0% 173
8.1% 173
8.2% 173
8.4% 173
8.5% 173
8.8% 173
9.0% 173
9.2% 173
9.3% 173
9.4% 173
9.5% 173
9.6% 173
doubled 173
Five-year 173
Rates 173
remainder 173
ROS1-E32 173
775 174
African 174
African-Americans 174
AIAN 174
Americans 174
Asian 174
Asians 174
Black 174
Caucasians 174
commercially 174
Distribution 174
East 174
Eth 174
Gh 174
KP 174
Native 174
NHPI 174
NHW 174
non-Hispanic 174
Non-Hispanic 174
Pacific 174
Proportion 174
Race 174
representation 174
RoW 174
SWM 174
Whi 174
White 174
Whites 174
PAC 175
screened 175
ac 176
catumaxomab 176
comb 176
Conc 176
cyc 176
eva 176
exp 176
fo 176
gas 176
goserelin 176
ia 176
ial 176
ian 176
ib 176
ic 176
ica 176
idence 176
ien 176
ients 176
ies 176
imen 176
ine 176
ing 176
int 176
ion 176
ions 176
isease 176
ith 176
ity 176
iv 176
iva 176
ive 176
lat 176
le 176
les 176
lin 176
lizumab 176
ll 176
ls 176
lts 176
mon 176
pat 176
po 176
rea 176
rece 176
red 176
reg 176
resu 176
rma 176
ro 176
su 176
ted 176
tenance 176
tmen 176
tr 176
tudy 176
vac 176
wi 176
zumab 176
M 177
R 177
discontinue 178
discontinuing 178
lapsed 178
NE 178
neu 178
OVC 178
PD 178
PEMBRO 178
Pre 178
tx 178
CL 179
Cmax 179
D29 179
DhExe 179
Exe 179
exhibited 179
Frequencies 179
genotyped 179
HNI 179
metabolite 179
ranged 179
SN38 179
steady-state 179
t1 179
UGT2B17 179
CGA 180
DLL3 180
ED 180
extensive 180
NEPC 180
Rova-T 180
SCLC 180
Bev 181
comparative 181
GDP 181
IA 181
IIIA 181
launched 181
LCNEC 181
mid 181
NEC 181
population 181
sizes 181
acquisition 182
architecture 182
Besides 182
burdens 182
cancerous 182
classifications 182
clonal 182
Clonal 182
concordance 182
concordant 182
contribution 182
degree 182
discordant 182
evolution 182
exhibit 182
fraction 182
fre 182
gITH 182
hematopoiesis 182
heterogeneity 182
LNM 182
Moreover 182
pairs 182
path 182
quency 182
reflect 182
reveals 182
shared 182
spectrum 182
subclonal 182
subclones 182
tected 182
temporal 182
TERTp 182
tracking 182
virtually 182
wide 182
Activity 183
adolescent 183
adolescents 183
alveolar 183
ASPS 183
AYA 183
blastoma 183
Brien 183
cediranib 183
Chris 183
embryonal 183
EWS 183
giant 183
Lifehouse 183
neuroblastoma 183
O 183
olaratumab 183
pazopanib 183
Pazopanib 183
pediatric 183
Ph2 183
RMS 183
sarcoma 183
Sarcoma 183
Sarcomas 183
SFT 183
soft 183
tazemetostat 183
Wilms 183
BINI 184
binimetinib 184
BRAFm 184
BRAF-mutant 184
BRAF-mutated 184
BRAFV600 184
BRAFV600-mutant 184
cobimetinib 184
CTX 184
dabrafenib 184
ENCO 184
encorafenib 184
MEK 184
mel 184
mutation-positive 184
PTC 184
trametinib 184
V. 184
V600 184
vemurafenib 184
Vemurafenib 184
261 185
276 185
277 185
284 185
285 185
286 185
303 185
311 185
322 185
395 185
576 185
601 185
ABCG2 185
Association 185
Biology 185
globally 185
Myeloid 185
Relationship 185
TOP-1 185
233 186
248 186
252 186
269 186
271 186
312 186
334 186
372 186
379 186
391 186
403 186
408 186
411 186
415 186
416 186
418 186
424 186
427 186
438 186
440 186
444 186
446 186
549 186
25.8% 187
carbo 187
centrally 187
cis 187
equal 187
LS 187
platin 187
SqCC 187
Then 187
Weekly 187
666 188
Beyer 188
Blood 188
Brain 188
Disease 188
Evaluable 188
Group 188
Independent 188
International 188
IWG 188
Marrow 188
Mets 188
mITT 188
ranges 188
Staging 188
Working 188
001 189
003 189
009 189
01 189
02 189
03 189
04 189
05 189
06 189
08 189
09 189
alleles 189
DQB1 189
DRB1 189
HLA-A 189
Both 190
BRAFi 190
complex 190
cuAEs 190
gain 190
MEKi 190
173 191
221 191
294 191
297 191
306 191
313 191
317 191
321 191
331 191
353 191
376 191
377 191
392 191
406 191
412 191
436 191
439 191
447 191
498 191
523 191
602 191
4.03 192
Adverse 192
Analyses 192
Common 192
Criteria 192
CTCAE 192
Events 192
graded 192
severity 192
Terminology 192
Toxicity 192
v3 192
v4 192
V4 192
version 192
2018 193
bank 193
board 193
CAs 193
cessation 193
computing 193
CPR 193
CTM 193
CTs 193
dedicated 193
evidence-based 193
expert 193
expertise 193
experts 193
guidance 193
IBM 193
implementation 193
implementing 193
INEN 193
interview 193
language 193
learned 193
marketing 193
medical 193
MTB 193
Navya 193
notes 193
nurse 193
ommendations 193
ommended 193
Oncologists 193
organization 193
protocols 193
provision 193
QCDR 193
radiologists 193
rec 193
specialists 193
staff 193
structured 193
Through 193
TMC 193
trained 193
unstructured 193
Watson 193
WFO 193
adenomas 194
adjusting 194
Adjusting 194
alcohol 194
aNSCLC 194
anti-PD1s 194
black 194
category 194
CCI 194
Charlson 194
Charlson-Deyo 194
chart-based 194
code-based 194
comor 194
comorbid 194
comorbidities 194
comorbidity 194
Comorbidity 194
controlling 194
COPD 194
demographic 194
Deyo 194
differed 194
distance 194
ences 194
ethnicity 194
facility 194
Females 194
gender 194
geographic 194
GFR 194
impacted 194
income 194
jects 194
MAN 194
marital 194
Marital 194
married 194
morbidities 194
newsprint 194
PMT 194
PPI 194
race 194
receipt 194
residence 194
SES 194
sex 194
Sex 194
Smoking 194
socio 194
socioeconomic 194
statin 194
stratum 194
tobacco 194
type 194
univariable 194
Variables 194
white 194
whites 194
Younger 194
accurate 195
accurately 195
actionability 195
actual 195
agement 195
aggressiveness 195
aid 195
assign 195
assist 195
BIC 195
call 195
clinician 195
Clinicians 195
contributing 195
curability 195
cure 195
DA 195
decision-making 195
discussed 195
easily 195
easy 195
egies 195
expectations 195
flexible 195
helpful 195
impacting 195
interactive 195
interpreted 195
involve 195
knowledge 195
learning 195
maximize 195
monitors 195
objectively 195
overtreatment 195
patient-centered 195
practical 195
preserve 195
process 195
psycho-oncological 195
PULSES 195
racially 195
refine 195
reliably 195
requirements 195
simple 195
strat 195
stratifying 195
sults 195
tailored 195
technical 195
tool 195
tools 195
UD 195
uncertainty 195
unnecessary 195
VF 195
web-based 195
workflow 195
worry 195
biology 196
cation 196
considerably 196
detailed 196
details 196
dif 196
differing 196
era 196
examines 196
ference 196
ferences 196
ferent 196
ILC 196
impacts 196
influencing 196
outcome 196
regard 196
adherence 197
Adherence 197
advised 197
Are 197
BCSR 197
chemoprevention 197
Findings 197
Genetics 197
Hereditary 197
HRMC 197
mammogram 197
MRMC 197
Nepal 197
Pap 197
perception 197
Prevention 197
Preventive 197
rural 197
screening 197
Self-reported 197
smear 197
statins 197
Surgeon 197
USPSTF 197
veillance 197
Very 197
W 197
154 198
220 198
224 198
314 198
316 198
318 198
325 198
330 198
332 198
553 198
605 198
Classification 198
adeno 199
adenocarcinomas 199
adenoid 199
bronchial 199
cancers 199
carcinoid 199
carcinoma 199
carcinomas 199
cervix 199
cholangiocarcinoma 199
cystic 199
differentiated 199
docrine 199
duct 199
ductal 199
gallbladder 199
HGG 199
histologies 199
intrahepatic 199
lobular 199
mediastinum 199
medullary 199
metaplastic 199
mucinous 199
muscle-invasive 199
neuroendocrine 199
ovary 199
pancreas 199
papillary 199
predominant 199
squa 199
testis 199
thyroid 199
undifferentiated 199
uterine 199
541 200
ASCOv1 200
ASCOv2 200
Benefits 200
coefficient 200
coefficients 200
Cohen 200
collectively 200
conferred 200
Differences 200
fair 200
icantly 200
Important 200
indirect 200
medium 200
QALYs 200
rho 200
signif 200
Spearman 200
Stat 200
statistical 200
threshold 200
thresholds 200
weighted 200
007 201
48.4% 201
52.3% 201
66.9% 201
77.1% 201
accounted 201
adherent 201
Ashkenazi 201
blacks 201
BRCA-associated 201
CH 201
college 201
COMPASS 201
concerned 201
discordance 201
distributed 201
educated 201
EF 201
first-degree 201
GO 201
heard 201
Hispanic 201
Hispanics 201
household 201
Jewish 201
KCRG 201
LatAm 201
Less 201
MAM 201
mark 201
menopause 201
nationally 201
Neg 201
non-carriers 201
nonelderly 201
parents 201
patient-provider 201
Personal 201
Pos 201
respondents 201
school 201
unadjusted 201
unchanged 201
usage 201
varied 201
VUS 201
subsequent 202
acid 203
acids 203
amino 203
calorie 203
causing 203
content 203
CRF 203
dependency 203
disruption 203
EXCAP 203
exercisers 203
fat 203
fatty 203
HLA-DQB1 203
inversely 203
LFS 203
mediating 203
mediators 203
memory 203
mitochondrial 203
mm3 203
modules 203
MT-CO2 203
mtDNA 203
muscle 203
MYH8 203
MYL5 203
OXA-PNP 203
resting 203
Significant 203
sured 203
Under 203
up-regulated 203
vari 203
139 204
140 204
146 204
159 204
189 204
209 204
246 204
279 204
319 204
414 204
44.1% 204
45.1% 204
503 204
504 204
507 204
510 204
520 204
528 204
562 204
572 204
604 204
878 204
GB 204
advantage 205
BC 205
diverse 205
kinetics 205
lacking 205
suggested 205
T. 205
CA-125 206
calculation 206
co-primary 206
Co-primary 206
correlative 206
end-point 206
endpoint 206
end-points 206
endpoints 206
Endpoints 206
event-free 206
Exploratory 206
HA 206
IMCgp100 206
intent-to-treat 206
investigator-assessed 206
jective 206
objective 206
objectives 206
ondary 206
PFS6 206
ploratory 206
PPS 206
pre-specified 206
primary 206
Primary 206
pt-reported 206
randomisation 206
rate 206
Sec 206
secondary 206
Secondary 206
vival 206
ypT0 206
AAT 207
activity 207
alkylating 207
animal 207
anoma 207
anti-tumor 207
Combined 207
CXCR4 207
CYP17 207
cytidine 207
demonstrates 207
desirable 207
driven 207
dual 207
exerts 207
exhibits 207
experiments 207
feedback 207
fusion-positive 207
HER3 207
HGF 207
inhibit 207
inhibition 207
in-vivo 207
long-lasting 207
lyase 207
monotherapies 207
potency 207
pre-clinical 207
preclinical 207
Pre-clinical 207
Preclinical 207
preclinically 207
Preclinically 207
rationale 207
sensitizes 207
sistance 207
synergism 207
synergistic 207
Taselisib 207
topoisomerase 207
transgenic 207
transiently 207
95 208
CAML 208
CAMLs 208
mm 208
accuracy 209
AJCC-N 209
avoid 209
axillary 209
cDLMs 209
CEUS 209
CK19 209
cN 209
contained 209
converting 209
CTLG 209
definitions 209
discrimination 209
drawn 209
false 209
LSG 209
lymphatic 209
margin 209
nodal 209
nomogram 209
NPV 209
nSLN 209
performing 209
prediction 209
PST 209
re-biopsy 209
reliable 209
rN 209
Sensitivity 209
SLN 209
Specificity 209
staging 209
surgeon 209
valid 209
VAT 209
ycT 209
ypN0 209
ypN 209
BOR 210
deviation 210
domains 210
FACT-G 210
FT 210
global 210
grading 210
instruments 210
item 210
items 210
measures 210
PAM 210
PAMs 210
post-baseline 210
PRO 210
QL2 210
Relationships 210
scale 210
scales 210
self-report 210
sessment 210
steps 210
wearable 210
absent 211
Also 211
changed 211
correlated 211
including 211
indicative 211
majority 211
moderately 211
Neither 211
nuclei 211
percentage 211
proportion 211
consisting 212
ability 213
adequately 213
ap 213
availability 213
concern 213
coordinated 213
disapproval 213
effort 213
elements 213
ETCTN 213
INC 213
indications 213
link 213
LOI 213
LOIs 213
par 213
PIs 213
policies 213
Potentially 213
presumed 213
processes 213
products 213
reasons 213
region 213
relationships 213
scientific 213
share 213
TCA 213
AdjCT 214
ddTC 214
EarlyR 214
EarlyRHigh 214
features 214
histologic 214
IDFS 214
intrinsic 214
Mesenchymal 214
MT 214
OWBC 214
RCB 214
relation 214
subtype 214
subtypes 214
YWBC 214
0.0003 215
0.0007 215
0.041 215
0.13 215
0.14 215
0.16 215
0.20 215
0.23 215
0.24 215
0.26 215
0.32 215
0.35 215
0.36 215
0.39 215
0.41 215
0.43 215
0.48 215
21.5% 215
3.55 215
83.3% 215
CD74 215
MA-RT 215
MOS 215
non-significant 215
pronounced 215
SA6RT 215
Similarly 215
tended 215
CE 216
concurrent 216
concurrently 216
hour 216
irinotecan 216
manner 216
tolerance 216
UGT1A1 216
absolute 217
adjust 217
adjusted 217
benefiting 217
conditional 217
covariates 217
cox 217
Cox 217
Cox-proportional 217
curves 217
DRP 217
esti 217
fitted 217
hazard 217
hazards 217
Kaplan-Meier 217
KM 217
Landmark 217
log-rank 217
logrank 217
Log-rank 217
Log-Rank 217
multivariable 217
Multivariable 217
multivariate 217
Multivariate 217
MV 217
portional 217
proportional 217
regression 217
Statistics 217
stepwise 217
Stratified 217
time-dependent 217
univariate 217
Univariate 217
168 218
185 218
213 218
219 218
230 218
238 218
251 218
256 218
260 218
264 218
274 218
278 218
281 218
288 218
296 218
298 218
302 218
320 218
324 218
327 218
335 218
337 218
338 218
340 218
341 218
343 218
345 218
346 218
347 218
348 218
349 218
351 218
354 218
355 218
356 218
357 218
359 218
369 218
384 218
394 218
404 218
405 218
413 218
419 218
421 218
422 218
429 218
431 218
432 218
4.55% 218
482 218
497 218
508 218
509 218
525 218
542 218
552 218
567 218
569 218
585 218
596 218
614 218
642 218
670 218
Concordance 218
Others 218
Use 218
approached 219
care 219
centre 219
clinic 219
gynecologic 219
hospitals 219
middle 219
outpatient 219
palliative 219
referral 219
referred 219
supportive 219
teaching 219
tertiary 219
unit 219
visit 219
written 219
2.95 220
abdomen 220
AD 220
all-cause 220
cc 220
CSI 220
cu 220
CUM 220
Event 220
exposed 220
Heart 220
HF 220
HI 220
HPV-SMN 220
LUQ 220
posed 220
Q1 220
Q2 220
Q3 220
Q4 220
SMR 220
splenectomy 220
whilst 220
292 221
ages 221
categorized 221
classified 221
diagnosed 221
ICD 221
linked 221
NAA 221
newly 221
searched 221
BRPC 222
initial 222
OPC 222
PP 222
radical 222
remaining 222
S 222
12.4% 223
12.5% 223
30.6% 223
47.3% 223
90.9% 223
ASP8273 223
ex19del 223
GNE 223
gradual 223
L858R 223
LAP 223
note 223
passed 223
plications 223
275 224
Bologna 224
dei 224
Fondazione 224
HGESS 224
IRCCS 224
Istituto 224
Italian 224
Italy 224
la 224
LGESS 224
lo 224
Milan 224
Nazionale 224
Oncologico 224
Paolo 224
Spanish 224
Tumori 224
Veneto 224
483 225
cfDNA 225
copies 225
Cssmin 225
ctDNA 225
D15 225
EOT 225
genotype 225
ng 225
plasma 225
postop 225
TFx 225
Arizona 226
AZ 226
Case 226
Cleveland 226
Clinic 226
Diane 226
Insitute 226
Mayo 226
MN 226
OH 226
Phoenix 226
Reserve 226
Rochester 226
Taussig 226
Western 226
FUP 227
GCT 227
GCTs 227
germ 227
HDCT 227
localized 227
malignancy 227
multimodality 227
poor-risk 227
RIS 227
SM 227
STET 227
trunk 227
CNI 228
detecting 228
detection 228
Detection 228
HPV-detect 228
magnetic 228
monitoring 228
multiparameter 228
resonance 228
2004 229
advanced-stage 229
Base 229
CAC 229
Database 229
Effective 229
FL3 229
Georgia 229
hospital-based 229
NCDB 229
ONSCLC 229
queried 229
SGC 229
stages 229
T1N0 229
TTI 229
Bronx 230
Brunswick 230
Columbia 230
Cornell 230
Fertility 230
Jersey 230
Kettering 230
Langone 230
Memorial 230
Montefiore 230
New 230
NJ 230
NY 230
NYU 230
Presbyterian 230
Rutgers 230
Sloan 230
Weil 230
Weill 230
York 230
York-Presbyterian 230
PTS 231
REG 231
regorafenib 231
TAS-102 231
BOM 232
residual 232
subpopulation 232
survivals 232
systemically 232
cluding 233
current 233
evaluated 233
laboratory 233
State 233
1302 234
4230 234
ABBV-221 234
AFR 234
AGEN1884 234
ALKS 234
ALRN-6924 234
ARRY-382 234
AZD2811 234
CUDC-907 234
CX-072 234
dose-escalation 234
EC1456 234
EFNA4 234
enoblituzumab 234
ERY974 234
es 234
escalation 234
expansion 234
explores 234
FIH 234
first-in 234
first-in-human 234
folate 234
fractory 234
GBR 234
Ia 234
IIa 234
INVAC-1 234
M7824 234
MBC-11 234
MCLA-128 234
MEDI0562 234
nanoparticle 234
ONX-0801 234
overexpressing 234
pansion 234
Part 234
Parts 234
PF-06647263 234
PGV001 234
PT-112 234
rolling 234
RP2D 234
SCB01A 234
segment 234
solid 234
subjects 234
Ti-061 234
TK216 234
two-part 234
U3-1402 234
WT2725 234
XMT-1522 234
ZW25 234
algorithm 235
analytical 235
ANGIOPREDICT 235
applied 235
assembled 235
build 235
built 235
characteristic 235
classifier 235
clinical-genomic 235
clustered 235
clustering 235
clusters 235
correctly 235
cross-validation 235
dataset 235
datasets 235
dichotomized 235
discriminating 235
feature 235
four-gene 235
generate 235
hierarchical 235
ICGC 235
informative 235
machine 235
miRNA 235
predictions 235
probes 235
ranked 235
set 235
sets 235
signature 235
silico 235
SVM 235
TCGA 235
top 235
training 235
transcript 235
typing 235
unsupervised 235
Unsupervised 235
validated 235
validation 235
achieving 236
ASXL1 236
BCR-ABL 236
blasts 236
CCyR 236
CD34 236
CEBPA 236
CLAD 236
CPC 236
CR1 236
CRi 236
CRp 236
DAC10 236
diminished 236
DNMT3A 236
duction 236
FIA 236
FLT3 236
FLT3-ITD 236
GV 236
IIT 236
ITD 236
LDAC 236
med 236
MRD 236
MRD-ve 236
mRUNX1 236
NPM1 236
pracinostat 236
RUNX1 236
sAML 236
TET2 236
TP53-MUT 236
WBC 236
aberration 237
aberrations 237
adenoma 237
alteration 237
alterations 237
amplifications 237
carcinogenesis 237
characterized 237
co-occurring 237
defining 237
deletion 237
designated 237
Different 237
driver 237
drivers 237
druggable 237
fusion 237
fusions 237
harbor 237
IFS 237
involving 237
lecular 237
MAs 237
metanephric 237
muta 237
mutagenesis 237
MyPathway 237
NKTL 237
NTRK 237
occur 237
oncogenic 237
origins 237
rangements 237
rare 237
rear 237
rearrangements 237
recurring 237
SMO 237
targetable 237
translocation 237
translocations 237
tumorigenesis 237
uncommon 237
unresponsive 237
adaptive 238
allowing 238
anti-PDL1 238
broader 238
broadly 238
capable 238
CED 238
cellular 238
CMB305 238
cognate 238
creating 238
cured 238
DCs 238
delivering 238
delivery 238
directly 238
eat 238
elicit 238
enabling 238
engagement 238
enhance 238
expand 238
facilitates 238
host 238
ICT 238
ideal 238
immuno 238
immunogenic 238
labeled 238
mapping 238
modulate 238
natural 238
partly 238
priming 238
recognition 238
recognizing 238
specific 238
stimulated 238
systems 238
transfer 238
triggering 238
TTI-621 238
unique 238
vaccine 238
vaccines 238
advantages 239
agents 239
anticancer 239
attractive 239
chemotherapeutic 239
compounds 239
development 239
emerging 239
exploit 239
FDA-approved 239
immunomodulatory 239
immunotherapeutic 239
malignancies 239
Novel 239
Numerous 239
off-label 239
PNAS 239
spherogenesis 239
STAT3-driven 239
target 239
targeting 239
targets 239
therapeutic 239
therapies 239
Class 240
CM 240
GEP 240
MSS 240
AG-120 241
ALM 241
ATRX 241
dehydrogenase 241
epigenetic 241
EZH2 241
HG 241
histone 241
IDH1 241
intact 241
isocitrate 241
MDM2 241
mIDH1 241
mIDH2 241
notably 241
oncometabolite 241
p53 241
phenotype 241
profound 241
RAF 241
SF3B1 241
spliceosome 241
splicing 241
accelerate 242
ALCHEMIST 242
approach 242
approaches 242
biomarker-driven 242
clinical 242
combine 242
complementary 242
computational 242
context 242
customized 242
DFCI 242
directed 242
efficient 242
enable 242
establishing 242
evolving 242
exclude 242
facilitate 242
future 242
generating 242
genomics 242
geted 242
highlighted 242
Identification 242
immuno-oncology 242
incorporating 242
innovative 242
insight 242
insights 242
intended 242
interpretation 242
intriguing 242
medicine 242
modular 242
molecularly 242
multi-site 242
offer 242
offering 242
offers 242
opportunities 242
orphan 242
paradigm 242
personalized 242
precision 242
Precision 242
prioritized 242
priority 242
progresses 242
prove 242
provide 242
providing 242
question 242
rational 242
regime 242
rently 242
science 242
serves 242
strategy 242
success 242
targeted 242
therapeutics 242
urgently 242
variety 242
WINTHER 242
1975 244
ADCAs 244
ago 244
astatic 244
BCC 244
charts 244
clinicopathologic 244
conflicting 244
controversial 244
curative-intent 244
de-identified 244
epidemiological 244
evalu 244
HDGC 244
identi 244
identified 244
I-III 244
IRB-approved 244
LDCT 244
MSKCC 244
scope 244
SMART 244
unknown 244
verified 244
advances 245
apeutic 245
believed 245
challenge 245
challenging 245
considerable 245
decades 245
deeper 245
Despite 245
dramatic 245
eventually 245
excellent 245
existing 245
fail 245
Given 245
growing 245
helped 245
HER21 245
historically 245
holds 245
However 245
hypothesized 245
increasing 245
increasingly 245
Individualized 245
Investigation 245
lack 245
leads 245
limitation 245
limitations 245
limited 245
limits 245
minority 245
modern 245
modest 245
Nevertheless 245
numerous 245
options 245
overcome 245
poses 245
progress 245
promise 245
recognized 245
relapsing 245
remains 245
represent 245
represents 245
require 245
strategies 245
suboptimal 245
substantial 245
typically 245
ultimately 245
universal 245
unmet 245
widespread 245
696 246
chart 246
conducted 246
differs 246
epidemiology 246
experience 246
institutional 246
literature 246
ments 246
meta-analysis 246
multi-institutional 246
NACD 246
NRCT 246
published 246
PubMed 246
retrospective 246
Retrospective 246
single-institution 246
systematic 246
underrepresented 246
asymptomatic 247
Average 247
drop 247
HBC 247
initiating 247
LVEF 247
medications 247
Rx 247
safely 247
SCTx 247
TT 247
aged 248
experiencing 248
listed 248
managed 248
OR 248
patterns 248
Additional 249
analyze 249
assess 249
association 249
associations 249
blocker 249
But 249
characterize 249
comprehensively 249
determine 249
differences 249
estimating 249
evaluate 249
evant 249
examine 249
examining 249
explore 249
explored 249
Here 249
hypothesize 249
identify 249
impact 249
influence 249
investigate 249
outcomes 249
quence 249
relationship 249
relevance 249
report 249
robust 249
Thus 249
We 249
Body 250
Bone 250
Cooperative 250
Eastern 250
Karnofsky 250
KPS 250
mance 250
Max 250
palliation 250
perfor 250
PRE 250
Site 250
A1 251
artery 251
contact 251
ejection 251
hepatic 251
liver 251
mCi 251
mesenteric 251
portal 251
systolic 251
TB 251
upper 251
vein 251
ventricular 251
wall 251
fracture 252
HT 252
Met 252
metformin 252
Mt 252
PI 252
STI 252
Atlanta 253
Barcelona 253
Boston 253
Brigham 253
Dana-Farber 253
General 253
Harvard 253
Hebron 253
MA 253
Madrid 253
Massachusetts 253
Sara 253
Spain 253
Vall 253
VHIO 253
Winship 253
AOEs 254
CML-CP 254
CP-CML 254
DAS 254
dasatinib 254
DASISION 254
intolerant 254
introduction 254
KI 254
manage 254
MCyR 254
modifications 254
NCT01207440 254
PACE 254
ponatinib 254
Sorafenib 254
VOEs 254
cCR 255
clonality 255
complete 255
correlating 255
non-progression 255
non-responders 255
patho 255
responder 255
responders 255
responding 255
response 255
responses 255
retreatment 255
sponse 255
ITT 256
Netherlands 256
recurrence-free 256
relapse-free 256
RFS 256
stromal 256
synchronous 256
alts 257
CPIs 257
DDR 257
established 257
integrated 257
ML 257
network 257
capacity 258
causal 258
colonoscopy 258
diet 258
dietary 258
discrepancies 258
disposition 258
ETT 258
fiber 258
glycemic 258
healthy 258
height 258
influenced 258
influences 258
insulin 258
intake 258
inverse 258
lifestyle 258
lifetime 258
lowest 258
magnitude 258
mis 258
modifiable 258
modify 258
obesity 258
PanC 258
protective 258
sedentary 258
Smaller 258
sociation 258
Str 258
strength 258
structure 258
survivor 258
tanning 258
tween 258
water 258
CMS 259
consensus 259
optimal 259
Using 259
CVAEs 260
dence 260
effects 260
ob 260
period 260
served 260
Summary 260
worsening 260
zation 260
IC 261
IFNGS 261
TC 261
MC 262
sociated 262
T790M 262
case-control 263
CCS 263
CCSS 263
childhood 263
Childhood 263
Children 263
Cincinnati 263
Endothelial 263
Jude 263
Lifetime 263
medulloblastoma 263
Memphis 263
nested 263
Pediatric 263
Sick 263
SJLIFE 263
St 263
Study 263
Survivor 263
survivors 263
AML 264
AZA 264
AZD 264
decitabine 264
higher-risk 264
HMA 264
HMAs 264
hypomethylating 264
MDS 264
Rigo 264
algorithms 265
amount 265
applying 265
assumption 265
average 265
averaged 265
birth 265
correct 265
counted 265
covered 265
created 265
descriptive 265
donors 265
draw 265
economical 265
EHR 265
extract 265
extraction 265
generated 265
geographically 265
implemented 265
inability 265
informatics 265
informed 265
input 265
inputs 265
KCR 265
lated 265
Linear 265
live 265
matching 265
media 265
Model 265
net 265
NLP 265
package 265
participant 265
plan 265
prepared 265
PT 265
qualitative 265
read 265
regular 265
software 265
SPS 265
standardized 265
standards 265
summarize 265
themes 265
VHVT 265
weights 265
activities 266
aerobic 266
AET 266
ANCOVA 266
antibiotics 266
app 266
balm 266
BBT-CI 266
bed 266
CARE 266
CBT 266
CCF 266
circadian 266
compliance 266
delivered 266
diary 266
documentation 266
E1308 266
E2399 266
EASE 266
eating 266
exercise 266
Exercise 266
FACT-HN 266
feeding 266
Fitbit 266
haloperidol 266
HRV-B 266
IG 266
intervention 266
mindfulness 266
minocycline 266
minutes 266
mobile 266
nutrition 266
ONS 266
OT 266
OTT 266
Participants 266
passive 266
Patch 266
phone 266
poster 266
post-intervention 266
post-op 266
RASS 266
rhythm 266
scheduled 266
sessions 266
shared-care 266
skills 266
SPEP 266
supervised 266
tervention 266
TH 266
usual 266
vaginal 266
VHNSS 266
waitlist 266
augmented 267
chemically 267
demonstrated 267
environment 267
extended 267
Furthermore 267
GC 267
increases 267
lipid 267
sug 267
Taken 267
1022 268
chromatography 268
clearance 268
cleared 268
limit 268
mass 268
Minimal 268
normalized 268
spectrometry 268
tandem 268
achievement 269
appropriately 269
clinically 269
consistent 269
consistently 269
hold 269
interruptions 269
lowered 269
modification 269
reach 269
reductions 269
remarkable 269
steady 269
yielded 269
451 270
Adj 270
Duration 270
Free 270
Full 270
Mixed 270
Mortality 270
Negative 270
Not 270
Nuclear 270
Progression 270
Ratio 270
Specific 270
Status 270
Survival 270
Therapy 270
Time 270
Unknown 270
Value 270
Visceral 270
Year 270
acneiform 271
alanine 271
alkaline 271
ALT 271
aminotransferase 271
amylase 271
appetite 271
arthralgia 271
aspartate 271
AST 271
attributed 271
attribution 271
causality 271
CK 271
Ctrough 271
dehydration 271
diarrhoea 271
discontinuations 271
dizziness 271
drug-related 271
dry 271
dysgeusia 271
el 271
ele 271
electrolyte 271
elevation 271
enzymes 271
G1-2 271
G1 271
G2 271
G3 271
G4 271
grade 271
grades 271
hand 271
headache 271
HFS 271
hyper 271
hyperbilirubinemia 271
hyperglycemia 271
hyperphosphatemia 271
hypertension 271
hypo 271
hypokalemia 271
hypophosphatemia 271
hypotension 271
lation 271
LFTs 271
lipase 271
myalgia 271
neuropathy 271
neutrophils 271
occurring 271
phosphatase 271
ported 271
proteinuria 271
pruritus 271
rash 271
reaction 271
sensory 271
shock 271
sidered 271
tox 271
TrAEs 271
transient 271
triglycerides 271
vision 271
weakness 271
abnormal 272
abnormalities 272
AFIB 272
allergic 272
atrial 272
autoimmune 272
bilirubin 272
BP 272
cardiac 272
cations 272
congestive 272
corticosteroids 272
cytopenias 272
DILI 272
disorders 272
dyspnea 272
effec 272
elevations 272
encephalopathy 272
episode 272
event 272
failure 272
fatal 272
fever 272
fibrillation 272
G5 272
heme 272
HTN 272
hypophysitis 272
IDH-DS 272
insufficiency 272
interruption 272
LFT 272
meningitis 272
myositis 272
neurologic 272
neutropenic 272
non-hematologic 272
occurrence 272
pancreatitis 272
permanent 272
QTc 272
resolved 272
respiratory 272
retinal 272
reversible 272
SAE 272
seizure 272
sepsis 272
severe 272
SPMs 272
steroid 272
steroids 272
Substantial 272
syndrome 272
thromboembolic 272
tocilizumab 272
toxicity 272
transaminases 272
transaminitis 272
unrelated 272
Actionable 273
ARID1A 273
ARID2 273
ATC 273
CCND1 273
CDKN2A 273
chromatin 273
commonly 273
CRGA 273
deleted 273
ERBB 273
ERBB3 273
FGFR1 273
FGFR2 273
frequent 273
frequently 273
Fusions 273
GAs 273
inactivating 273
inactivation 273
JAK1 273
JAK2 273
JAK-STAT 273
lacked 273
NF2 273
nsSNP 273
NTRK1 273
NTRK2 273
NTRK3 273
oncogene 273
oncogenes 273
partners 273
PBRM1 273
PI3KCA 273
pnsSNPs 273
polymorphism 273
RTK 273
RTKs 273
scribed 273
SETD2 273
SMAD4 273
SMARCA4 273
SMARCB1 273
SNF 273
subunit 273
SWI 273
Tazemetostat 273
TERT 273
TKD 273
YES1 273
ACA 274
Act 274
Affordable 274
anti-dementia 274
anti-myeloma 274
articles 274
billion 274
Com 274
Costs 274
countries 274
coverage 274
enrollees 274
expenditures 274
gap 274
generic 274
HDHP 274
healthcare 274
insurers 274
LIS 274
mbc 274
Medicare 274
Nearly 274
oncolytics 274
OOP 274
out-of-pocket 274
payment 274
Payment 274
persons 274
plans 274
pocket 274
policy 274
prescription 274
prescriptions 274
Price 274
public 274
recipients 274
reimbursed 274
rising 274
sharing 274
shift 274
spending 274
Spending 274
trajectories 274
Aberrant 275
activator 275
acts 275
afenib 275
arrest 275
assembly 275
b-catenin 275
Bcl-2 275
BET 275
biosynthesis 275
chemical 275
Chk1 275
constitutive 275
degradation 275
differentiation 275
disrupts 275
down-regulation 275
downstream 275
EBP-a 275
enzyme 275
ERK 275
exclusively 275
extracellular 275
Hedgehog 275
hy 275
implicated 275
inhibiting 275
Inhibition 275
inhibits 275
intracellular 275
involved 275
isoforms 275
key 275
leading 275
liferation 275
localization 275
mammalian 275
matrix 275
mediator 275
membrane 275
metabolism 275
mixture 275
MMP9 275
modulating 275
modulator 275
Notch 275
nuclear 275
oncogenesis 275
overexpression 275
pathway 275
pathways 275
phosphorylated 275
phosphorylation 275
PI3K-AKT 275
potently 275
promote 275
promoted 275
proteins 275
Ras 275
reactivation 275
regulate 275
regulates 275
regulation 275
regulator 275
remodeling 275
replication 275
retinoic 275
reversed 275
S6 275
Selective 275
selectively 275
signaling 275
signalling 275
spindle 275
Src 275
SRC 275
suppress 275
suppressed 275
tential 275
TGF-b 275
transcription 275
TTK 275
Wee1 275
Wnt 275
WNT 275
1000 276
100 276
1200 276
625 276
900 276
A2 276
admin 276
B1 276
B2 276
bd 276
BD 276
BGJ 276
BIW 276
C1 276
C1D15 276
C2 276
C6 276
Ctroughfirst-dose 276
cycle 276
cycles 276
D1 276
dacarbazine 276
day 276
days 276
DL1 276
DL2 276
DL3 276
Dose-limiting 276
Dosing 276
Etoposide 276
G-CSF 276
geometric 276
istered 276
Level 276
loading 276
m2 276
Maximum 276
mcg 276
nab-p 276
nP 276
onwards 276
pl 276
q21 276
Q21 276
q2 276
Q 276
q3 276
q3wk 276
q3wks 276
QOD 276
QW 276
ranging 276
Starting 276
TAX 276
TCID50 276
TIW 276
ug 276
weeks 276
0.059 277
12.8 277
15.6 277
16.0 277
16.1 277
16.4 277
17.0 277
17.8 277
18.2 277
19.5 277
20.0 277
20.6 277
21.4 277
21.9 277
22.7 277
23.2 277
23.7 277
24.4 277
25.2 277
25.3 277
25.4 277
26.8 277
27.8% 277
28.3 277
29.2 277
29.3 277
29.4 277
30.3 277
32.6 277
35.3 277
36.1 277
36.8 277
39.7 277
41.2 277
45.7 277
46.4 277
47.1 277
47.7 277
48.4 277
48.6 277
52.9 277
53.2 277
55.9 277
58.4 277
58.8 277
59.5 277
60.0 277
62.3 277
63.9 277
66.7 277
69.2 277
69.3 277
75.0 277
78.6 277
86.3 277
8.9 277
Difference 277
Dyspnea 277
Mean 277
Placebo 277
P-Value 277
RECOURSE 277
acquired 278
activating 278
Afa 278
afatinib 278
Afatinib 278
amp 278
benefited 278
C797 278
C797S 278
EGF816 278
EGFR 278
EGFR-mutant 278
EGFR-mutated 278
EGFR-TKI 278
EGFR-TKIs 278
erlotinib 278
ex18m 278
Ex20ins 278
Ex20Ins 278
exon 278
fication 278
gefitinib 278
gen 278
harboring 278
harbouring 278
HER2-mutant 278
II-IIIA 278
L792 278
lung 278
mech 278
mEGFR 278
MET 278
osi 278
OSI 278
osimertinib 278
Osimertinib 278
platforms 278
resistance 278
</s> 278
sensitizing 278
T790M-positive 278
Unfortunately 278
568 279
Activating 279
BRAF 279
Comparative 279
ERBB2 279
IMPACT 279
METD14 279
nsSNPs 279
represented 279
Result 279
RET-rearranged 279
S492R 279
STK11 279
SV 279
V600E 279
407 280
correlates 280
Role 280
AutoHCT 281
backbone 281
BR 281
chemoimmunotherapy 281
CNSL 281
consolidative 281
COT 281
DA-R-EPOCH 281
DR 281
extranodal 281
immunochemotherapy 281
indolent 281
iNHL 281
modalities 281
MPV 281
px 281
R-CHOP 281
RCHOP 281
R-CVP 281
RCVP 281
RI 281
rituximab 281
salvage 281
Salvage 281
stem-cell 281
VAC 281
Academy 282
Affiliated 282
Asan 282
Beijing 282
Chest 282
Chiba 282
Chinese 282
Choi 282
College 282
cology 282
Department 282
Dublin 282
Education 282
Emory 282
Faculty 282
Fudan 282
Fukuoka 282
gery 282
GGH 282
Graduate 282
Guangdong 282
Guangzhou 282
Hospital 282
Internal 282
Ji 282
Jiaotong 282
Jin 282
Kang 282
Laboratory 282
Li 282
Lim 282
Locally 282
Maastricht 282
ME 282
Nanjing 282
non-small-cell 282
Pancreatic 282
partment 282
Peking 282
Republic 282
Russia 282
Sciences 282
Seoul 282
Shanghai 282
Shizuoka 282
Sichuan 282
sity 282
small-cell 282
Sur 282
Surgeons 282
Surgery 282
Technology 282
Third 282
Tokyo 282
Ulsan 282
Union 282
van 282
VU 282
Wakayama 282
Walter 282
Wang 282
Wei 282
Won 282
Yat-sen 282
Yat-Sen 282
Yokohama 282
Yonsei 282
Young 282
Zhang 282
Zhu 282
1250 283
1800 283
2400 283
3600 283
375 283
475 283
575 283
750 283
AUC5 283
bolus 283
Carboplatin 283
CIV 283
CMAB009 283
conjunction 283
d1 283
d1-3 283
D1-3 283
D2 283
Deflexifol 283
fluorouracil 283
folinic 283
Fu 283
Ifosfamide 283
infusional 283
Irinotecan 283
leucovorin 283
LV5FU2 283
m² 283
MMC 283
Oxaliplatin 283
PLD 283
replaced 283
Selinexor 283
sequential 283
simplified 283
TF 283
ABBV-399 284
ACC 284
AX 284
CBD 284
CCA 284
CM082 284
CZ 284
dose-expansion 284
dose-finding 284
DTC 284
EXP 284
FTD 284
GBq 284
HCC 284
MTC 284
Ph1 284
RAI 284
RD 284
REGO 284
rHGG 284
sorafenib 284
tepotinib 284
THC 284
TPI 284
TRK 284
Twelve 284
vandetanib 284
account 285
attempt 285
Bayesian 285
Carlo 285
exceeds 285
food 285
individual 285
methods 285
mixed 285
modeling 285
NONMEM 285
proach 285
probability 285
separately 285
step 285
variability 285
varying 285
134 286
138 286
181 286
205 286
231 286
247 286
282 286
310 286
339 286
362 286
397 286
401 286
448 286
449 286
454 286
460 286
465 286
469 286
470 286
505 286
512 286
513 286
518 286
531 286
533 286
536 286
538 286
543 286
556 286
559 286
565 286
574 286
637 286
726 286
737 286
740 286
769 286
802 286
932 286
943 286
975 286
Rest 286
Two-year 286
USD 286
adding 287
benefit 287
confirms 287
confounded 287
efficacious 287
extend 287
front 287
main 287
opportunity 287
prolong 287
prolonging 287
real 287
removal 287
setting 287
survive 287
therapy 287
treatment 287
treatments 287
uated 287
upfront 287
vary 287
0.010 288
EGFRi 288
HUS 288
LCR 288
NBM 288
NCF 288
numerical 288
quantity 288
reflecting 288
remained 288
S4LC 288
SLD 288
SSD 288
TVS 288
worst 288
BCS 289
DCIS 289
DS 289
E5194 289
estimates 289
LR 289
ODC 289
risks 289
Antoine 290
AP-HP 290
Bordeaux 290
Campus 290
Caroline 290
Curie 290
Dermatology 290
desmoid 290
du 290
France 290
French 290
Georges 290
Gustave 290
Hopital 290
Institut 290
Le 290
Lille 290
Luis 290
Lyon 290
Marseille 290
ˆo 290
Oscar 290
Paris 290
Paris-Sud 290
pital 290
Poland 290
Pompidou 290
Prognosis 290
rard 290
retinoblastoma 290
Roussy 290
Saint 290
Service 290
soft-tissue 290
Sophie 290
Therapies 290
Timone 290
Villejuif 290
102 291
113 291
116 291
119 291
155 291
267 291
668 291
AG 291
conclusion 291
Estimated 291
HA-High 291
HFSR 291
KELIM 291
MABp1 291
MR4 291
MWA 291
PAG 291
Assessing 292
consideration 292
decisions 292
diagnostic 292
early-stage 292
guide 292
guiding 292
How 292
integrate 292
Is 292
management 292
Predictors 292
Prospective 292
RECIST1 292
routine 292
Routine 292
routinely 292
utility 292
validate 292
valuable 292
BCSS 293
CD11b 293
CD163 293
CD3 293
CD4 293
CD45 293
CD68 293
CD8 293
co-expression 293
CTLs 293
cycling 293
densities 293
density 293
Expression 293
FDR 293
Flow 293
Foxp3 293
FoxP3 293
FOXP3 293
G-MDSC 293
GRP78 293
HLA-DR 293
IE 293
IIS 293
Immunoscore 293
infiltrated 293
infiltrates 293
infiltrating 293
inflamed 293
intraepithelial 293
KAMS 293
log2 293
lymphocytes 293
M1 293
M2 293
mac 293
macrophages 293
Marker 293
MDSC 293
mm2 293
preserved 293
proliferating 293
Select 293
stroma 293
TIL 293
TILs 293
TNBCs 293
absence 294
brain 294
cerebral 294
intracranial 294
Intracranial 294
ıve 294
lytic 294
metas 294
penetration 294
requiring 294
tases 294
tomatic 294
ADL 295
Anxiety 295
Assessment 295
Beck 295
BFI 295
Brief 295
Burden 295
Cognitive 295
Depression 295
Edmonton 295
ESAS 295
FACT 295
FACT-P 295
Fatigue 295
Form 295
Function 295
Functional 295
Geriatric 295
Global 295
HADS 295
IADL 295
instrument 295
Inventory 295
Life 295
Living 295
mea 295
MFI 295
Multidimensional 295
Nail 295
NRS 295
Organization 295
Outcome 295
Performance 295
Physical 295
PROs 295
Questionnaire 295
Scale 295
Severity 295
Short 295
Social 295
subscale 295
Survey 295
Symptom 295
Test 295
Visual 295
Worst 295
attained 296
B-ALL 296
Brentuximab 296
demonstrating 296
dismal 296
durability 296
durable 296
Durable 296
enasidenib 296
E-sel 296
extramedullary 296
maintaining 296
mission 296
morphologic 296
NCT01044069 296
Relapses 296
remissions 296
sponses 296
sustained 296
tend 296
toxic 296
ULMs 296
308 297
basal 297
class-I 297
clinico 297
correlation 297
DOD 297
infiltrate 297
necrosis 297
NED 297
NSGCT 297
pathologic 297
Pathologic 297
pathological 297
pCR 297
position 297
positively 297
PTB 297
pure 297
R1 297
R2 297
sponders 297
TME 297
Tregs 297
adulthood 298
age-based 298
assurance 298
BCRL 298
BIS 298
CD 298
collect 298
collects 298
cross-sectional 298
curable 298
Detailed 298
health-related 298
longitudinal 298
MKI 298
nature 298
neurocognitive 298
oncological 298
painful 298
patient-reported 298
PBTS 298
regularly 298
RIFTOS 298
sectional 298
sign 298
symp 298
undertaken 298
unplanned 298
YA 298
26.1% 299
abundant 299
antigens 299
B2M 299
clones 299
clonotypes 299
Collectively 299
Conversely 299
correlate 299
crease 299
de-novo 299
displayed 299
enriched 299
existence 299
Finally 299
heavy 299
IL10 299
infrequent 299
intra 299
Lastly 299
Levels 299
marked 299
metabolic 299
mune 299
neoepitopes 299
phenomenon 299
predicted 299
retained 299
Strikingly 299
Such 299
suggesting 299
suggestive 299
TAMs 299
640 300
ANC 300
BG 300
cholesterol 300
CrCl 300
creatinine 300
dL 300
DMB 300
glucose 300
Hb 300
hemoglobin 300
hours 300
hr 300
min 300
minute 300
mmol 300
neutrophil 300
platelet 300
platelets 300
prevented 300
SDS 300
Weight 300
ZA 300
classic 301
ependymoma 301
glioma 301
gliomas 301
IDH 301
LGG 301
low-grade 301
MUT 301
rRS 301
tissues 301
Unlike 301
ag 302
aggressive 302
complexity 302
Current 302
Currently 302
develop 302
Due 302
exists 302
gressive 302
heterogeneous 302
occurs 302
paucity 302
predictable 302
rarity 302
Recently 302
regarded 302
Several 302
Studies 302
universally 302
Upfront 302
126 303
Change 303
conversion 303
CTC0 303
declined 303
definition 303
distribution 303
missing 303
Positive 303
continue 304
continued 304
continuing 304
indoximod 304
PEM 304
sipuleucel-T 304
acteristics 305
alyzed 305
Analysis 305
analyzed 305
balanced 305
Baseline 305
Cases 305
char 305
charac 305
character 305
characteristics 305
Characteristics 305
Demographic 305
demographics 305
Out 305
Pt 305
teristics 305
ABC 306
Endocrine 306
Everolimus 306
EXE 306
exemestane 306
ful 306
Fulvestrant 306
MONALEESA-2 306
NCT01958021 306
PAL 306
palbo 306
Palbo 306
Palbociclib 306
PALOMA-1 306
PALOMA-3 306
visceral 306
89.6% 307
comparisons 307
cor 307
CxRT 307
CxT 307
DDFS 307
DDRD 307
DFS 307
disease-free 307
distant 307
Distant 307
DMFS 307
DRFS 307
DSS 307
importantly 307
LG 307
low-PNI 307
metastasis-free 307
mp53 307
PPD 307
Relapse 307
tastasis 307
TBC 307
TTR 307
069 308
APD 308
cutaneous 308
fractionation 308
High-dose 308
IPI 308
ipilimumab 308
MEL 308
MUM 308
NIVO 308
PAN 308
schemes 308
select 308
UM 308
uveal 308
antibody-drug 309
conjugate 309
doxorubicin 309
liposomal 309
Rovalpituzumab 309
SC 309
tesirine 309
vedotin 309
Adults 310
CAR 310
CAR-T 310
CD19 310
CD19-specific 310
CRS 310
CTL019 310
CTL119 310
cytokine 310
D28 310
deep 310
EM 310
expanded 310
fell 310
JCAR017 310
lysis 310
neurotoxicity 310
NTX 310
NY-ESO-1c259T 310
pe 310
peak 310
persistence 310
recovered 310
reinfusion 310
release 310
sNTX 310
splenomegaly 310
heteroclitic 311
HPV16 311
MMP 311
NG 311
overlapping 311
peptide 311
peptides 311
pool 311
reactivity 311
sequences 311
TGN 311
vaccinated 311
vaccination 311
volunteers 311
WT1 311
colorectal 312
CRC 312
deficient 312
dMMR 312
ECs 312
instability 312
lorectal 312
mCRC 312
microsatellite 312
mismatch 312
MMR 312
MSI 312
MSI-H 312
proficient 312
0.00001 313
0.0001 313
0.0002 313
0.0005 313
0.0006 313
0.0009 313
0.0011 313
0.002 313
0.011 313
0.012 313
0.013 313
0.014 313
0.018 313
0.019 313
0.021 313
0.027 313
0.028 313
0.034 313
0.036 313
0.038 313
0.039 313
0.040 313
0.042 313
0.044 313
0.046 313
0.048 313
0.051 313
0.052 313
0.058 313
0.065 313
0.097 313
14.9% 313
1.80 313
1.98 313
1.99 313
3.15 313
ATB 313
Interaction 313
ms 313
ns 313
p-value 313
P-value 313
quartile 313
Responders 313
AE37 314
Antonio 314
Aung 314
Carlos 314
CSCC 314
ECHO-202 314
epacadostat 314
Epacadostat 314
HDAC 314
hedgehog 314
hepatocellular 314
I 314
Initial 314
Interim 314
Investigational 314
KEYNOTE-037 314
Naing 314
nucleoside 314
oncolytic 314
pan-HER 314
Preliminary 314
START 314
treatment-refractory 314
ADP-ribose 315
ATR 315
BRCAness 315
breaks 315
compromised 315
damage 315
damaging 315
defect 315
defective 315
defects 315
deficiencies 315
deficiency 315
display 315
heterozygosity 315
hibitors 315
homologous 315
HRD 315
Inhibitors 315
lethality 315
Loss 315
Nature 315
NI 315
PARP-1 315
PARP 315
PARPi 315
PDCLs 315
poly 315
Poly 315
polymerase 315
recombination 315
rely 315
repair 315
restore 315
sensitive 315
stability 315
susceptible 315
synthetic 315
tran 315
underlie 315
wildtype 315
bulk 316
captured 316
ccRCC 316
cluster 316
Crohn 316
Differential 316
differentially 316
enrichment 316
expression 316
FC 316
Gene 316
germ-line 316
HLA 316
Ig 316
lineage 316
loads 316
LSC 316
mRNA 316
myeloid-B 316
myeloid-T 316
NanoString 316
OPLs 316
PAX8 316
PCC 316
PGL 316
phenotypic 316
pression 316
RNA-seq 316
RNA-sequencing 316
SCBC 316
T-ALL 316
TCR 316
TCRb 316
termed 316
transcriptomic 316
transcripts 316
exams 317
FDG 317
GPA 317
guided 317
maps 317
measurements 317
metrics 317
mpMRI 317
MTV 317
perfusion 317
PI-RADS 317
Quantitative 317
radiomic 317
radiomics 317
raw 317
scan 317
scans 317
SUV 317
TA 317
texture 317
TLG 317
tortuosity 317
uptake 317
v2 317
Version 317
vessel 317
vessels 317
WB-DWI 317
108 318
125 318
127 318
131 318
133 318
135 318
137 318
145 318
147 318
151 318
153 318
161 318
163 318
225 318
3000 318
304 318
Developmental 318
Discovery 318
Experimental 318
First-in-human 318
Immunotherapy 318
Pharmacology 318
Therapeutics 318
bilateral 319
CNS 319
http 319
involvement 319
nervous 319
non-CNS 319
non-measurable 319
ocular 319
PCNSL 319
RB 319
RONI 319
SCNSL 319
chemistry 320
codeletion 320
Longitudinal 320
p19q 320
quantified 320
1010 321
affinity 321
AFM26 321
AT1413 321
B7-H3 321
BCMA 321
beads 321
bearing 321
CD28 321
Cells 321
CIF 321
classical 321
comprises 321
culture 321
D3 321
delivers 321
derived 321
encoding 321
engineered 321
EphA2 321
epitope 321
epitopes 321
express 321
expressing 321
formulated 321
genetically 321
glycoprotein 321
HSP70 321
IL-2 321
inactive 321
interleukin-2 321
isoform 321
lentiviral 321
leukocyte 321
loaded 321
LV305 321
lymphoid 321
MAGE 321
MAGE-A10 321
NKG2D 321
NY-ESO-1 321
NY-ESO 321
optimized 321
over-expressed 321
overexpressed 321
PLA 321
plasmid 321
preferentially 321
reactive 321
simultaneously 321
SLFN11 321
surface 321
TCRs 321
TM 321
transfected 321
translation 321
transmembrane 321
vector 321
acti 322
activate 322
activated 322
activates 322
ADCC 322
alters 322
antibody-dependent 322
anti-MM 322
attack 322
augment 322
cell 322
cell-mediated 322
cells 322
COM701 322
CSF1 322
cytotoxic 322
cytotoxicity 322
dendritic 322
depend 322
depletion 322
dioxygenase 322
endogenous 322
enhanced 322
enhances 322
evade 322
fibroblasts 322
hibition 322
IDO 322
IL-12 322
immune-mediated 322
immunity 322
immunosuppression 322
immunosuppressive 322
indoleamine 322
induce 322
induced 322
induces 322
inducing 322
inhibitory 322
innate 322
interferon 322
Intratumoral 322
IPA 322
ITK 322
killer 322
killing 322
mediate 322
mediated 322
microenvironment 322
monocytes 322
murine 322
myeloid-derived 322
NK 322
NK-cell 322
overcoming 322
phagocytosis 322
prevents 322
produce 322
produced 322
production 322
proliferation 322
proliferative 322
promotes 322
renders 322
Resiquimod 322
sip-T 322
stimulates 322
stimulation 322
suppresses 322
suppression 322
synergistically 322
T-cells 322
TLR 322
TMEM 322
tumor-associated 322
upregulates 322
vestigated 322
VISTA 322
ascending 323
By 323
CC 323
colon 323
colonic 323
distal 323
flexure 323
left-sided 323
located 323
location 323
PETACC-8 323
rectum 323
right-sided 323
splenic 323
4000 324
accelerated 324
alternate 324
amended 324
amendment 324
AUC0-12h 324
calation 324
chosen 324
continuous 324
DE 324
design 324
DL 324
DLs 324
DLT 324
DLTs 324
dose 324
Dose 324
dose-limiting 324
doses 324
dosing 324
enroll 324
escalated 324
flat 324
icities 324
IDD 324
imum 324
intermittent 324
intra-patient 324
limiting 324
LMP776 324
LTLD 324
MAD 324
maximal 324
maximum 324
ministered 324
ministration 324
MR-HIFU 324
MTD 324
od 324
Once 324
Palb 324
parallel 324
phases 324
portion 324
reassessment 324
recommended 324
Recommended 324
Ribociclib 324
RP2 324
run-in 324
schedule 324
Schedule 324
schedules 324
schema 324
scheme 324
Selumetinib 324
starting 324
successive 324
TAL 324
taladegib 324
Tas 324
TID 324
tier 324
titration 324
tolerated 324
TThP 324
weekly 324
80% 325
90% 325
accrued 325
achieves 325
alpha 325
assumed 325
assuming 325
Assuming 325
ATs 325
CCCA 325
detect 325
dropout 325
error 325
favoring 325
H0 325
hypothesis 325
level 325
null 325
one-sided 325
PFS12w 325
power 325
powered 325
proceed 325
reject 325
rejected 325
rules 325
sided 325
significance 325
Simon 325
size 325
superiority 325
TVB-2640 325
two-sided 325
two-stage 325
absorbed 326
additive 326
bination 326
bioavailability 326
CB-1158 326
dosage 326
dose-dependent 326
dose-proportional 326
drug-drug 326
evi 326
half-life 326
increase 326
mately 326
observed 326
obvious 326
on-target 326
raising 326
supporting 326
Tmax 326
window 326
adds 327
aims 327
define 327
devel 327
drive 327
immunotherapies 327
observations 327
on-going 327
opment 327
peutic 327
potential 327
responsiveness 327
thera 327
types 327
100% 328
52% 328
56% 328
57% 328
58% 328
68% 328
69% 328
70% 328
72% 328
73% 328
74% 328
75% 328
76% 328
78% 328
79% 328
81% 328
82% 328
83% 328
84% 328
85% 328
86% 328
87% 328
88% 328
89% 328
91% 328
92% 328
93% 328
94% 328
96% 328
97% 328
98% 328
99% 328
At 328
DPAM 328
nr 328
PMCA 328
PPV 328
WE 328
allowed 329
Assessments 329
Cheson 329
clude 329
CTCAEv4 329
extracranial 329
IMWG 329
irRC 329
irRECIST 329
Lugano 329
pexidartinib 329
progressive 329
RANO 329
RECISTv1 329
uation 329
volumetric 329
broad 330
DD 330
failed 330
INI1 330
lines 330
LPS 330
WD 330
ASCT 331
CD138 331
CD38 331
color 331
Connect 331
CPCs 331
MFC 331
MGUS 331
MM 331
multiple 331
myeloma 331
Myeloma 331
NDMM 331
SMM 331
smoldering 331
undetermined 331
0.0 332
0.1 332
0.2 332
0.3 332
0.4 332
0.6 332
0.7 332
0.9 332
1.0 332
1.2 332
1.3 332
1.4 332
1.5 332
1.6 332
1.7 332
1.8 332
1.9 332
2.0 332
2.1 332
2.2 332
2.3 332
2.4 332
2.5 332
2.6 332
2.7 332
2.8 332
2.9 332
3.0 332
3.1 332
3.2 332
3.3 332
3.4 332
3.5 332
3.6 332
3.7 332
3.8 332
4.0 332
4.2 332
4.3 332
4.4 332
4.5 332
4.7 332
4.8 332
4.9 332
Percent 332
Ref 332
x10-5 332
BORR 333
CaboNivo 333
CaboNivoIpi 333
Con 333
Confirmed 333
cORR 333
cPR 333
CRs 333
cutoff 333
DCO 333
DCR 333
efficacy-evaluable 333
ESC 333
evaluable 333
Gb 333
HCV 333
I1 333
I3 333
Investigator-assessed 333
KN158 333
Line 333
N3 333
non-CRC 333
OCT2016 333
ORR 333
ORRs 333
post-platinum 333
PRs 333
pts 333
rd-line 333
SACTx 333
sor 333
unconfirmed 333
uPR 333
abscopal 334
action 334
anti-tumour 334
appeared 334
BGB-A317 334
biologically 334
BMS-986156 334
CART-133 334
CEA 334
couraging 334
CPI-444 334
ditional 334
G100 334
GDC-0919 334
Infusion 334
JS001 334
liminary 334
LTX-315 334
manageable 334
MRG-106 334
NKR-2 334
PG545 334
Pharmacokinetics 334
Promising 334
REGN2810 334
RO6958688 334
S1 334
S2 334
SD-101 334
signals 334
unexpected 334
well-tolerated 334
50.4 335
825 335
anal 335
beneficiaries 335
boost 335
borderline 335
bulky 335
CCRT 335
Cervical 335
cGy 335
chemoradiation 335
chemoradiotherapy 335
chemo-RT 335
chemoRT 335
cisplatin-based 335
cisplatinum 335
concomitant 335
Concurrent 335
conformal 335
consolidation 335
CRT 335
cT3 335
CTRI 335
de-escalated 335
de-escalation 335
diotherapy 335
ERT 335
esophagectomy 335
fractions 335
GKS 335
GTV 335
Gy 335
IG-IMRT 335
III-IVB 335
IMRT 335
intensified 335
intensity-modulated 335
LARC 335
LA-SCCHN 335
lymphadenectomy 335
mesorectal 335
modulated 335
Nimotuzumab 335
one-cycle 335
pelvic 335
PF 335
preop 335
preoperative 335
Preoperative 335
Radiotherapy 335
SCRT 335
TNT 335
TPF 335
transoral 335
trimodality 335
Adult 336
anti-angiogenic 336
ation 336
caused 336
Cisplatin 336
Combining 336
DMF 336
function 336
HDC 336
impaired 336
Newly 336
newly-diagnosed 336
PA 336
potentiates 336
TRC102 336
uncontrolled 336
Bu 337
Flu 337
HD 337
HV 337
LD 337
106 338
107 338
109 338
124 338
329 338
transduced 338
x109 338
chain 339
curative 339
Del-1 339
exosomal 339
FLC 339
inflammatory 339
intent 339
investigated 339
light 339
Monitoring 339
032 340
adv 340
anti-PD 340
Atezo 340
atezolizumab 340
Atezolizumab 340
avelumab 340
Avelumab 340
BMS-986016 340
brolizumab 340
CheckMate 340
demon 340
eval 340
gressed 340
HF10 340
JAVELIN 340
KEYNOTE-045 340
KEYNOTE-086 340
lumab 340
mUC 340
multicohort 340
naive 340
NCT01772004 340
NCT02105636 340
NCT02155647 340
Nivo 340
Nivolumab 340
OAK 340
pem 340
pembro 340
pembrolizumab 340
Pembrolizumab 340
platinum-refractory 340
Pooled 340
strated 340
TBP 340
urothelial 340
virus-associated 340
ABP 341
alyses 341
anti-drug 341
CA125 341
correlations 341
dictive 341
dimensions 341
elimination 341
fasting 341
hair 341
kinetic 341
lationship 341
modeled 341
nonlinear 341
normalization 341
ordinal 341
parameter 341
parameters 341
pre-chemotherapy 341
pre-defined 341
pTie2 341
reflected 341
Regression 341
retention 341
Simulations 341
sion 341
termined 341
timepoints 341
trough 341
two-sample 341
EML4 342
IREs 342
mets 342
TPM 342
BLC 343
Commonly 343
DCB 343
EML4-ALK 343
Frequency 343
Genes 343
L-LCNEC 343
MB 343
megabase 343
Mel 343
MSI-high 343
mt 343
Mutational 343
non-NSCLC 343
NSCLCs 343
PRCC 343
TML 343
UtCa 343
Another 344
apparent 344
Biopsy 344
chose 344
diameters 344
differentiate 344
discriminate 344
lesion 344
lesions 344
MR 344
non-responder 344
non-target 344
pseudoprogression 344
PsP 344
radiographically 344
radiological 344
radiologically 344
Remaining 344
resolution 344
restaging 344
sum 344
true 344
265 345
adenosine 345
ARhigh 345
ARlow 345
defines 345
derive 345
discovery 345
DKK1 345
FPKM 345
IMMU-132 345
secreted 345
upregulated 345
092 346
ABT-888 346
ARQ 346
AZD2014 346
capsules 346
formulation 346
GOG 346
IMGN853 346
Lurbinectedin 346
mirvetuximab 346
nance 346
Nin 346
Niraparib 346
Ola 346
olap 346
olaparib 346
Olaparib 346
PM01183 346
PROC 346
PSR 346
Quisinostat 346
SOC 346
SOLO2 346
soravtansine 346
tablet 346
tablets 346
TALA 346
talazoparib 346
veliparib 346
velopment 346
vistusertib 346
wPxl 346
DDFPe 347
depending 347
doubling 347
IMP321 347
injected 347
injection 347
injections 347
NBTXR3 347
palpable 347
Post 347
reduction 347
SQ 347
Upon 347
vaccinations 347
VXM01 347
week 347
Any 348
Bladder 348
Histology 348
ISS 348
Kidney 348
L 348
Location 348
Mono 348
NA 348
Nephrectomy 348
pos 348
Triple 348
Y 348
Yes 348
antitumor 349
Antitumor 349
assesses 349
COH29 349
Correlative 349
demonstration 349
DS-7423 349
enter 349
establish 349
evaluation 349
evaluations 349
GSK3359609 349
jectives 349
LY 349
mab 349
MEDI3726 349
namics 349
Objectives 349
ongoing 349
phar 349
pharma 349
pharmacody 349
pharmacodynamic 349
pharmacodynamics 349
pharmacoki 349
pharmacokinetic 349
pharmacokinetics 349
PK 349
preliminary 349
profile 349
rollment 349
SM88 349
tivity 349
07 350
2016 350
April 350
As 350
Aug 350
August 350
Between 350
centres 350
consented 350
cut-off 350
Dec 350
December 350
Demographics 350
enrolled 350
Feb 350
February 350
From 350
Jan 350
January 350
Jul 350
July 350
Mar 350
March 350
Nov 350
November 350
Oct 350
October 350
pleted 350
recruited 350
rolled 350
Sep 350
Sept 350
September 350
000 351
reference 351
VS 351
BCG 352
bladder 352
CIS 352
Deg 352
ENDEAVOR 352
GM-CSF 352
GVAX 352
high-risk 352
HS-410 352
instillation 352
intermediate 352
intravesical 352
low-risk 352
Moreau 352
NMIBC 352
non-muscle 352
THP 352
Area 353
Centro 353
de 353
Enfermedades 353
fined 353
GEICO 353
ıa 353
Instituto 353
Lima 353
Moore 353
Nacional 353
novo 353
Oncolog 353
Oncologia 353
Peru 353
Red 353
141 354
first-line 354
GKRS 354
ILD 354
laBCC 354
Long 354
Long-term 354
perioperative 354
POST 354
reports 354
second-line 354
term 354
CgA 355
CLARINET 355
flushing 355
HIAA 355
LAN 355
NETs 355
nonresponders 355
OCT 355
OLE 355
PRRT 355
Radiographic 355
SRE 355
ULN 355
Wk 355
Aim 356
AMBRA 356
applicable 356
categories 356
choices 356
CHT 356
describes 356
DFI 356
ESME 356
ET 356
HER2-ve 356
real-life 356
SABCS 356
sequent 356
So 356
VTB 356
Cabazitaxel 357
gland 357
heavily 357
OVCA 357
pretreated 357
regimens 357
salivary 357
taxane 357
taxanes 357
compares 358
conclusions 358
equally 358
favorably 358
historical 358
immature 358
justified 358
Longer 358
mature 358
Mature 358
non-inferiority 358
observation 358
plateau 358
rates 358
relative 358
respect 358
Subgroup 358
tistically 358
UP 358
20.3% 359
50.5% 359
52.4% 359
88.2% 359
censoring 359
Clavien 359
complications 359
deaths 359
High-risk 359
HIV 359
infections 359
infectious 359
in-hospital 359
LAC 359
weekday 359
deemed 360
EGC 360
emerged 360
major 360
mela 360
MTBS 360
NAT 360
noma 360
Protocol 360
ARG1 361
ARV 361
associate 361
canonical 361
CD274 361
classifiers 361
closely 361
discovered 361
domain 361
EMT 361
EPCAM 361
expressions 361
fast 361
functionally 361
ge 361
gene 361
genomically 361
HER3-EGFR 361
HOTAIR 361
HOX 361
hypermutated 361
JUN 361
loci 361
mors 361
nomic 361
non-coding 361
Notably 361
phenotypes 361
protein 361
r2 361
SCNA 361
SCNAs 361
signatures 361
splice 361
structural 361
subset 361
terized 361
tumors 361
unstable 361
CellSearch 362
CSF 362
CTC 362
CTCs 362
enumeration 362
EpCAM 362
IGF1R 362
Trop2 362
academic 363
center 363
centers 363
centralized 363
II-III 363
individualized 363
meta 363
Patients 363
randomly 363
receive 363
retro 363
spective 363
standard 363
stratified 363
They 363
Vigil 363
aBSI 364
Activin 364
AFP 364
Alb 364
albumin 364
AMC 364
C1M 364
C4M 364
collagen 364
C-reactive 364
CRP 364
dl 364
dNLR 364
ECM 364
fragments 364
MPS 364
Myostatin 364
neutrophil-to-lymphocyte 364
NLR 364
On 364
Pro-C3 364
Protein 364
serum 364
sPDL1 364
uni 364
UNL 364
classification 365
expected 365
FOXO1 365
achieved 366
Best 366
CBR 366
Complete 366
Control 366
CR 366
CRu 366
Early 366
heavily-pretreated 366
lasting 366
mCR 366
non-progressive 366
Objective 366
partial 366
Partial 366
PR 366
Progressive 366
Prolonged 366
Rate 366
Response 366
SD 366
stabilization 366
stable 366
Stable 366
wk 367
wks 367
anti-CD19 368
antigen 368
Autologous 368
axi-cel 368
Axi-cel 368
bb2121 368
BB 368
CD133 368
chimeric 368
comprising 368
dur 368
HLA-A2 368
ICT-121 368
immunologic 368
investigates 368
KTE-C19 368
Lesokhin 368
refractory 368
ZUMA-1 368
aberrant 369
adhesion 369
ALCAM 369
alter 369
associ 369
bind 369
block 369
candidate 369
Cas9 369
cHL 369
circulation 369
component 369
components 369
contribute 369
CRISPR 369
DLC1 369
drives 369
editing 369
elucidated 369
endothelium 369
energy 369
escape 369
evasion 369
flammation 369
fumarate 369
glial 369
Importantly 369
inherent 369
interplay 369
machinery 369
master 369
mechanism 369
mechanisms 369
migration 369
negatively 369
networks 369
off-target 369
overcomes 369
partner 369
pathogenesis 369
pharmacologic 369
play 369
plays 369
progenitor 369
prominent 369
promoting 369
purified 369
regulated 369
regulating 369
regulators 369
responsible 369
roles 369
RSCs 369
stimulating 369
structures 369
suppressor 369
teraction 369
transcriptional 369
trigger 369
tumor-specific 369
UPR 369
epidermal 370
Epidermal 370
factor 370
Factor 370
FGF 370
FGFR 370
fibroblast 370
growth 370
Growth 370
platelet-derived 370
receptor 370
Receptor 370
RET 370
VEGFR 370
choice 371
complicated 371
CTRS 371
decision 371
IPAT 371
preferred 371
ST 371
st-line 371
ve 371
Akt 372
AKT 372
amplification 372
CDK6 372
ClinBen 372
cyclin 372
FGFR4 372
FGFRamp 372
FGFRinh 372
FGFRmut 372
GYN 372
Hh 372
HRAS 372
inh 372
MAPK 372
mRNAh 372
mTOR 372
PI3K 372
plification 372
Activation 373
anti 373
antibodies 373
anti-CTLA-4 373
anti-GD2 373
Anti-PD-1 373
Anti-PD1 373
anti-PD-L1 373
anti-programmed 373
axis 373
BCCs 373
blockade 373
blocking 373
check 373
checkpoint 373
Checkpoint 373
checkpoints 373
combining 373
CTLA-4 373
death-1 373
death-ligand 373
geting 373
ICIs 373
immunotherapy 373
IMT 373
L1 373
ligand 373
mAbs 373
malig 373
Monotherapy 373
PD-1 373
produces 373
programmed 373
Programmed 373
restoring 373
revolutionized 373
synergy 373
Targeting 373
T-lymphocyte 373
actionable 374
CAPP-Seq 374
cell-free 374
Cell-free 374
CGP 374
characterization 374
chemotherapy-resistant 374
companion 374
comprehensive 374
coupled 374
ct 374
diagnostics 374
discover 374
DNA 374
dynamic 374
evolutionary 374
genomic 374
Genomic 374
HGSC 374
highlights 374
identifies 374
identifying 374
landscape 374
liquid 374
Liquid 374
LUAD 374
molecular 374
Molecular 374
MpBC 374
named 374
non-invasive 374
PDA 374
precisely 374
profiles 374
profiling 374
Profiling 374
proteomic 374
reveal 374
serve 374
similarities 374
simultaneous 374
subtyping 374
Targeted 374
tissue-based 374
tumor-derived 374
undertook 374
AB 375
Baker 375
Benefit 375
Better 375
Calgary 375
Centre 375
Continued 375
Elderly 375
element 375
European 375
Experience 375
INSPIRE 375
MacCallum 375
Margaret 375
McGill 375
Network 375
Odette 375
ON 375
Ontario 375
Ottawa 375
Princess 375
Sunnybrook 375
Sydney 375
Toronto 375
Uni 375
versity 375
accounts 376
hallmark 376
involves 376
logic 376
mesenchymal 376
origin 376
transition 376
Although 377
beneficial 377
evidence 377
Limited 377
Our 377
proposed 377
Recent 377
role 377
strong 377
suggests 377
supports 377
These 377
While 377
anaplastic 378
astrocytoma 378
oligodendroglioma 378
P. 378
trend 378
10.0 379
10.3 379
10.5 379
10.6 379
11.2 379
11.5 379
11.6 379
12.5 379
12.7 379
13.0 379
13.5 379
15.5 379
16.3 379
17.5 379
21.2 379
21.6 379
3.9 379
4.1 379
4.6 379
5.0 379
5.1 379
5.2 379
5.3 379
5.4 379
5.5 379
5.6 379
5.7 379
5.8 379
5.9 379
6.0 379
6.1 379
6.2 379
6.3 379
6.4 379
6.5 379
6.6 379
6.7 379
6.8 379
7.0 379
7.1 379
7.2 379
7.3 379
7.4 379
7.5 379
7.7 379
7.8 379
7.9 379
8.0 379
8.1 379
8.2 379
8.3 379
8.5 379
8.7 379
8.8 379
9.0 379
9.2 379
9.3 379
9.4 379
9.5 379
9.7 379
9.9 379
CAB 379
CARB 379
cFAS 379
estimable 379
minus 379
mths 379
autopsy 380
biopsied 380
BMs 380
cerebrospinal 380
confirmation 380
cranial 380
CRPC-Adeno 380
cytology 380
disseminated 380
ease 380
extension 380
fluid 380
in-transit 380
mediastinal 380
Metastases 380
multifocal 380
PSMA-avid 380
recurred 380
repeat 380
Sites 380
specimen 380
suffered 380
suspected 380
suspicious 380
tracranial 380
anatomic 381
anatomical 381
avid 381
axial 381
confined 381
DM 381
Gender 381
LC 381
local 381
locations 381
metachronous 381
MIBG 381
MPT 381
MSF 381
organs 381
peri 381
site 381
solitary 381
toneal 381
carcinomatosis 382
CCC 382
EOC 382
epithelial 382
fallopian 382
FIGO 382
FRa 382
intraperitoneal 382
ovarian 382
peritoneal 382
PW-Post 382
tube 382
And 383
cytoreductive 383
debulking 383
HIPEC 383
hyperthermic 383
IDS 383
Local 383
NAC 383
NACT 383
neoadjuvant 383
postoperative 383
Postoperative 383
R0 383
Regional 383
surgery 383
wait 383
Academic 384
Anna 384
Austria 384
Bren 384
cal 384
Christian 384
Cologne 384
debate 384
der 384
DKFZ 384
Dresden 384
Erlangen 384
Essen 384
Frank 384
Gastric 384
German 384
Germany 384
Gynecology 384
Hamburg 384
Hamburg-Eppendorf 384
Heidelberg 384
Hong 384
IN 384
Indiana 384
Indianapolis 384
intergroup 384
Julia 384
KCSG 384
Kim 384
Klinik 384
Kliniken 384
Kong 384
Mannheim 384
Melvin 384
Min 384
Mumbai 384
Neu-Isenburg 384
non-interventional 384
NRG 384
NSABP 384
Obstetrics 384
Optimal 384
Radiation 384
Samsung 384
Surgical 384
Tata 384
Universitatsklinikum 384
Vancouver 384
Vienna 384
Yu 384
57.9% 385
invasion 385
logical 385
melanosis 385
neoplasia 385
nerve 385
palatal 385
pattern 385
peritoneum 385
presence 385
Presence 385
protect 385
Soft 385
UAT 385
veloped 385
Adenocarcinoma 386
Ca 386
Cancers 386
Carcinoma 386
Cell 386
Local-Regional 386
Lung 386
Metastatic 386
Non-Small 386
Other 386
Small 386
Squamous 386
Thoracic 386
Type 386
Urothelial 386
C3 387
CD30 387
CD30min 387
cy 387
E6 387
EoI 387
hu14 387
neg 387
ORR4 387
proceeded 387
BCI 388
EET 388
Estrogen 388
H 388
likelihood 388
LPBC 388
Predictive 388
Prognostic 388
0.00 389
0.037 389
0.064 389
0.27 389
0.28 389
0.29 389
0.30 389
0.31 389
0.33 389
0.34 389
0.37 389
0.38 389
0.40 389
0.42 389
0.44 389
0.45 389
0.46 389
0.47 389
0.49 389
0.50 389
0.51 389
0.52 389
0.53 389
0.54 389
0.55 389
0.56 389
0.57 389
0.58 389
0.59 389
0.60 389
0.61 389
0.62 389
0.63 389
0.64 389
0.65 389
0.66 389
0.67 389
0.68 389
0.69 389
0.70 389
0.71 389
0.72 389
0.73 389
0.74 389
0.75 389
0.76 389
0.77 389
0.78 389
0.79 389
0.80 389
0.81 389
0.82 389
0.83 389
0.84 389
0.85 389
0.86 389
0.87 389
0.88 389
0.89 389
0.90 389
0.91 389
0.92 389
0.93 389
0.94 389
0.95 389
0.96 389
0.97 389
0.98 389
1.00 389
2.00 389
53.7 389
5.78 389
95% 389
CI 389
HR 389
HRadj 389
liver-specific 389
NNT 389
nominal 389
P 389
anti-HBV 390
ART 390
Cardiac 390
cardiovascular 390
Cardiovascular 390
cumulative 390
CV 390
developing 390
diseases 390
excess 390
fractures 390
genitourinary 390
GERD 390
HBV 390
incidence 390
Incidence 390
Infection 390
late 390
Late 390
manifestations 390
mortality 390
NEN 390
neoplasms 390
Patterns 390
Poor 390
radiation-related 390
risk 390
SOT 390
SREs 390
stressful 390
Temporal 390
testicular 390
VTE 390
attempted 391
basis 391
collection 391
practice 391
Previously 391
real-time 391
requested 391
successful 391
surgeries 391
breast 392
Breast 392
CIOF 392
CONUT 392
extent 392
Index 392
Management 392
Mexico 392
MICRA 392
Nutritional 392
obese 392
Obesity 392
Pathology 392
PNI 392
women 392
Women 392
004 393
616 393
ADB 393
agreement 393
bankruptcy 393
CAGE-AID 393
cision 393
closer 393
decisional 393
difficulty 393
disagreement 393
distinction 393
expect 393
feel 393
ICC 393
indicating 393
Measures 393
non-adherent 393
numeracy 393
perfect 393
preparation 393
PSM 393
readers 393
recall 393
recalled 393
regret 393
Relative 393
SOAPP-14 393
TL 393
trust 393
values 393
accrual 394
Accrual 394
anticipated 394
assignment 394
bloods 394
boundaries 394
boundary 394
closed 394
closure 394
commenced 394
continues 394
crossed 394
decided 394
Enrollment 394
enrolment 394
Follow-up 394
futility 394
hypotheses 394
ineligibility 394
interim 394
met 394
OA 394
originally 394
pending 394
planned 394
predefined 394
prematurely 394
prespecified 394
recruit 394
recruitment 394
Recruitment 394
required 394
rule 394
sented 394
stopped 394
stopping 394
submission 394
Target 394
85.3% 395
agree 395
attempting 395
CIOFF 395
close 395
contralateral 395
CPM 395
definite 395
discrepancy 395
fertility 395
hysterectomy 395
mammography 395
menopausal 395
NSDBC 395
NST 395
OFR 395
Pathological 395
PDS 395
Percentage 395
post-surgery 395
pregnancy 395
preoperatively 395
procedures 395
proportions 395
Proportions 395
Regarding 395
Scores 395
SDBC 395
T2 395
Those 395
transgender 395
actively 396
biological 396
concept 396
consequence 396
Consequently 396
create 396
describing 396
driving 396
essential 396
highlighting 396
interactions 396
investigations 396
ITH 396
kinome 396
mechanistic 396
metabolomics 396
optimization 396
proof 396
propose 396
quantify 396
recruiting 396
released 396
relevant 396
148 397
158 397
166 397
268 397
425 397
487 397
496 397
516 397
636 397
90 397
99 397
Melanoma 397
Per 397
Skin 397
Validation 397
CIT 398
competing 398
death 398
recorded 398
TTSRE 398
volume 398
Within 398
ab 399
adjacent 399
archived 399
cellularity 399
delineate 399
histo 399
IBC 399
isolated 399
Lymphocyte 399
microscopic 399
morphology 399
mucosa 399
nanomechanical 399
NoA 399
ological 399
PAI-1 399
PBTC 399
portant 399
QCCs 399
qualify 399
RPS 399
surrounding 399
uPA 399
viscera 399
VRM 399
ablative 400
beam 400
brachytherapy 400
diation 400
external 400
field 400
fr 400
hypofractionated 400
intraoperative 400
IORT 400
irradiated 400
irradiation 400
oligometastatic 400
radiation 400
radio 400
radiosurgery 400
radiotherapy 400
RN 400
RT 400
SABR 400
SBRT 400
spinal 400
SRS 400
stereotactic 400
Stereotactic 400
WBRT 400
100.0% 401
175 401
850 401
AGC 401
AUC 401
BOL 401
CLR 401
CON 401
D8 401
inferiority 401
nab-PTX 401
non-inferior 401
PG 401
q1w 401
sb-PTX 401
SEQ 401
TDM 401
1679 402
bev 402
BV 402
CCL5 402
CCR5 402
cet 402
Cet 402
Colon 402
CRCs 402
DPD 402
DSLT 402
ERCC1 402
favor 402
FOLFIRI 402
FOLFOX 402
iri 402
LPT 402
Ox 402
polymorphisms 402
rs3212986 402
SAFL 402
sidedness 402
SL 402
SNPs 402
TRIBE 402
VEGFA 402
wild 402
0001 403
0.025 403
0.04 403
0.05 403
0.06 403
0.07 403
0.08 403
0.09 403
0.10 403
0.11 403
0.12 403
0.15 403
0.17 403
0.18 403
0.19 403
0.21 403
0.22 403
0.25 403
15.5% 403
ALB 403
cantly 403
difference 403
marginally 403
padj 403
Ptrend 403
SE 403
signifi 403
Similar 403
statistically 403
Std 403
trended 403
BREAK-2 404
critical 404
Emi 404
Liver 404
15.0% 405
15.6% 405
15.7% 405
16.4% 405
19.2% 405
19.6% 405
20.8% 405
23.1% 405
23.5% 405
29.7% 405
31.1% 405
33.8% 405
34.2% 405
35.8% 405
36.7% 405
38.2% 405
40.0% 405
42.0% 405
42.4% 405
43.2% 405
43.5% 405
44.8% 405
45.8% 405
46.8% 405
47.6% 405
48.3% 405
50.1% 405
51.7% 405
53.6 405
55.4% 405
55.6% 405
57.3% 405
59.3% 405
61.3% 405
61.4% 405
61.5% 405
63.6 405
64.3% 405
70.6% 405
72.1% 405
72.4% 405
73.1% 405
75.0% 405
76.5% 405
77.4% 405
79.5% 405
82.1% 405
83.7% 405
8.7% 405
87.5% 405
88.6% 405
93.3% 405
94.4% 405
94.5% 405
94.6% 405
97.5% 405
AC-T 405
AH 405
Arm1 405
Arm2 405
Arm3 405
AT 405
BCP 405
CbD 405
CFP 405
CG 405
C-high 405
EPC 405
Eso 405
Fewer 405
IIA 405
IIB 405
M1c 405
p16-positive 405
Thirty-four 405
VAIA 405
VG 405
18.5% 406
58.3% 406
CI95 406
Favorable 406
gardless 406
HGBLR 406
NF 406
NOS 406
SG 406
employed 407
pop 407
Statistical 407
studied 407
ulation 407
103 408
105 408
26 408
27 408
31 408
32 408
34 408
35 408
36 408
37 408
38 408
39 408
41 408
42 408
43 408
44 408
46 408
47 408
48 408
49 408
51 408
52 408
53 408
54 408
55 408
56 408
57 408
58 408
588 408
59 408
61 408
62 408
63 408
64 408
66 408
67 408
71 408
72 408
74 408
76 408
77 408
78 408
79 408
81 408
82 408
83 408
84 408
86 408
87 408
88 408
89 408
91 408
93 408
94 408
97 408
98 408
GETUG 408
WHITE 408
040 409
326 409
743 409
BMS 409
Checkmate 409
EAP 409
Efficacy 409
expanded-access 409
exploratory 409
Final 409
Pd 409
single-agent 409
Sor 409
Tolerability 409
treatment-naive 409
update 409
updated 409
Updated 409
children 410
confer 410
B-R 411
CHOP-R 411
CRD 411
CTD 411
DRd 411
DVd 411
ELd 411
Follow 411
KCd 411
KRd 411
Ld 411
MRD-negative 411
negativity 411
RAD 411
Rd 411
TE 411
TTNT 411
Vd 411
VGPR 411
VMP 411
VRD 411
10.1 412
10.2 412
10.4 412
10.7 412
10.8 412
10.9 412
11.0 412
11.1 412
11.3 412
11.4 412
11.7 412
11.9 412
12.0 412
12.1 412
12.2 412
12.4 412
12.6 412
12.9 412
13.1 412
13.3 412
13.4 412
13.6 412
13.7 412
13.8 412
13.9 412
14.1 412
14.4 412
14.6 412
14.8 412
14.9 412
15.2 412
15.7 412
15.9 412
16.2 412
16.5 412
16.6 412
17.3 412
17.4 412
17.9 412
18.3 412
18.7 412
19.4 412
19.6 412
19.8 412
19.9 412
20.1 412
20.4 412
21.7 412
21.8 412
22.3 412
23.1 412
23.5 412
24.1 412
26.5 412
27.7 412
28.7 412
28.8 412
29.5 412
30.2 412
30.8 412
32.1 412
32.9 412
33.5 412
34.2 412
36.5 412
7.6 412
8.4 412
9.6 412
9.8 412
C.I. 412
IC95 412
Km 412
months 412
mos 412
Vmax 412
BCR-ABL1 413
BOS 413
CML 413
cyto 413
exceptional 413
IFN 413
IM 413
lead 413
mGIST 413
Ph 413
BRCA 414
BRCAm 414
BRCA-mutated 414
BRCAwt 414
gBRCA 414
HGS 414
HGSOC 414
LGSOC 414
LOH 414
OC 414
OC-NS 414
OC-S 414
platinum-resistant 414
platinum-sensitive 414
reversion 414
revGA 414
serous 414
592 415
Atlas 415
depth 415
Genome 415
Mb 415
micro 415
Mutation 415
Nanostring 415
non-synonymous 415
nonsynonymous 415
sequenced 415
Somatic 415
tational 415
tional 415
TMB 415
Tumor 415
X. 415
Advanced 416
extremely 416
NB 416
NSCLC-ct 416
poor 416
Previous 416
prognosis 416
SCCC 416
SCLC-ct 416
ASN001 417
G 417
meaningful 417
132 418
biomarker 418
Biomarker 418
Considering 418
distinguish 418
ii 418
nivolumab 418
selection 418
validating 418
apoptosis 419
arginine 419
autophagy 419
Axl 419
BGB324 419
blot 419
BRD4 419
caspase 419
cleavage 419
colony 419
depleted 419
dimer 419
engraftment 419
HDAC11 419
IC50 419
inhibited 419
Kd 419
kill 419
KIT-mutant 419
knockdown 419
LC3 419
LMTK3 419
MIB 419
MIF 419
mM 419
modulation 419
mouse 419
native 419
nM 419
NSG 419
organoids 419
patient-derived 419
PDX 419
physiological 419
pM 419
preferential 419
principle 419
properties 419
restored 419
Robust 419
rodent 419
Rv1 419
shRNA 419
silencing 419
siRNA 419
species 419
SY-1425 419
viability 419
vitro 419
vivo 419
western 419
xenograft 419
xenografts 419
adjunct 420
aim 420
aimed 420
developed 420
effective 420
Hence 420
It 420
proved 420
Therefore 420
unclear 420
aCTLA4 421
aPD1 421
colitis 421
COMBO 421
curred 421
discontinuation 421
discontinued 421
Drug-related 421
experienced 421
G3-4 421
gr 421
hepatitis 421
immune-related 421
Immune-related 421
interrupted 421
irAE 421
irAEs 421
IRR 421
led 421
MONO 421
myocarditis 421
oc 421
occurred 421
pneumonitis 421
reported 421
resumed 421
resuming 421
retreated 421
seniors 421
TRAE 421
TRAEs 421
treatment-related 421
Treatment-related 421
acceptable 422
Adding 422
agent 422
cacy 422
combi 422
combination 422
combinations 422
effi 422
eribulin 422
ficacy 422
lurbinectedin 422
nation 422
nations 422
promising 422
safe 422
single 422
tolerable 422
unprecedented 422
advanced 423
biliary 423
BKM120 423
BTC 423
carci 423
CCR 423
cervical 423
curatively 423
ED-SCLC 423
ESCC 423
esophageal 423
esophagogastric 423
esophagus 423
gastric 423
gastro 423
gastroesophageal 423
inoperable 423
IVB 423
junction 423
KEYNOTE-059 423
LAPC 423
locally 423
locoregionally 423
metastatic 423
mFOLFOX6 423
MGC 423
nasopharyngeal 423
NENs 423
non-resectable 423
NPC 423
platinum-containing 423
resectable 423
sectable 423
transitional 423
UCC 423
unresectable 423
unresected 423
ade 424
adenocar 424
adenocarcinoma 424
biphasic 424
carcinosarcoma 424
cinoma 424
cytologically 424
endo 424
endometrioid 424
Endometrioid 424
extrahepatic 424
histological 424
Histological 424
histology 424
III-IV 424
Inclusion 424
intestinal 424
metrial 424
non-epithelioid 424
non-squamous 424
nonsquamous 424
ring 424
sarcomatoid 424
stomach 424
WHO 424
53.2% 425
578 425
A 425
ABCB1 425
arm 425
Arm 425
arms 425
Arms 425
B 425
C 425
Ced 425
CFI 425
DOX 425
gBRCAmut 425
Grp 425
HiVitD 425
LN-ve 425
LowVitD 425
non-gBRCAmut 425
Olap 425
Pw 425
R-C 425
WP 425
CMR 426
crossover 426
durations 426
free 426
GROC 426
HG-RFS 426
iii 426
intention 426
landmark 426
Letrozol 426
numerically 426
OS 426
Overall 426
PD2 426
PFS 426
post-progression 426
progression 426
progression-free 426
Progression-free 426
prolonged 426
QAS 426
respective 426
survival 426
TTF 426
VIC 426
yielding 426
ASTS 427
CP 427
cross-over 427
FAS 427
GMI 427
ICON 427
L-sarcomas 427
previous 427
RE 427
trabectedin 427
Addition 428
anthracycline-based 428
AP 428
capecitabine 428
Carbo 428
cetux 428
Chemo 428
concomitantly 428
ddAC 428
docetaxel 428
Docetaxel 428
dose-dense 428
epirubicin 428
Eribulin 428
experimental 428
FEC 428
FLOT 428
fol 428
HCQ 428
IP 428
lapatinib 428
lowed 428
nab 428
oxaliplatin-based 428
pac 428
paclitaxel 428
Paclitaxel 428
Perioperative 428
Pertuzumab 428
RAD001 428
Sequential 428
XELOX 428
XP 428
110 429
118 429
130 429
162 429
174 429
198 429
206 429
241 429
245 429
333 429
350 429
360 429
409 429
476 429
491 429
580 429
700 429
733 429
734 429
813 429
Groups 429
institutions 429
aVAT 430
binary 430
CA20 430
calibration 430
CIN25 430
c-index 430
C-index 430
covariate 430
curve 430
cut 430
cutoffs 430
cutpoint 430
cutpoints 430
dependently 430
divided 430
ELs 430
entire 430
equation 430
Hazards 430
LIR 430
LMR 430
MFS 430
MVI 430
ODX 430
operating 430
PDE4D7 430
PDGFA 430
PDGFD 430
plots 430
propensity 430
pT 430
quartiles 430
receiver 430
ROC 430
score 430
SUVave 430
tertile 430
tree 430
TRG 430
T-stage 430
variable 430
VAT-HU 430
23.3% 431
cm 431
CSS 431
currence 431
EBRT 431
Gleason 431
GR 431
GS 431
HDR-BT 431
IRP 431
LRR 431
N0 431
OM 431
PCSM 431
PN 431
pT2 431
pT3a 431
Size 431
T1a 431
T3a 431
termediate 431
ys 431
1500 432
840 432
administered 432
Cohorts 432
Cycle 432
Cycles 432
D 432
Day 432
Days 432
DUR 432
durvalumab 432
intra-T 432
intravenous 432
intravenously 432
Kg 432
MEDI4736 432
poly-ICLC 432
q28d 432
q2w 432
q2wk 432
q3w 432
q4w 432
Q4W 432
receives 432
sequentially 432
subcutaneous 432
TRE 432
tremelimumab 432
x3 432
AF 433
allele 433
cl 433
DRD 433
END 433
ESR1 433
FGFR3 433
H1047R 433
instances 433
mut 433
PAMi 433
PIK3CA 433
PTEN 433
SER 433
TSC1 433
TSC2 433
TTP 433
EBV 434
head 434
Head 434
HNC 434
HNSCC 434
HNSCCa 434
HPV2 434
HPV 434
HPV-negative 434
HPV-positive 434
Induction 434
in-situ 434
LA 434
LAHNC 434
neck 434
Neck 434
non-OPSCC 434
non-oropharyngeal 434
OPSCC 434
oropharyngeal 434
oropharynx 434
papillomavirus 434
pharyngeal 434
SCC 434
SCCHN 434
squamous 434
sSCC 434
vulvar 434
completely 435
compression 435
CRCLM 435
CRLM 435
DW-MRI 435
metastases 435
metastasis 435
operative 435
post-operative 435
procedure 435
resectability 435
RFA 435
robotic 435
Short-term 435
SIRT 435
suitable 435
tastases 435
achieve 436
autologous 436
cRIT 436
DIPG 436
I-8H9 436
MRCLS 436
MVT-5873 436
remain 436
viable 436
ABT-414 437
BEV 437
bio 437
CpG 437
CpGs 437
DSRCT 437
GBM 437
glioblastoma 437
IRI 437
LTS 437
methylated 437
methylation 437
methyltransferase 437
MGMT 437
multiforme 437
promoter 437
rGBM 437
temozolomide 437
TMZ 437
unmethylated 437
VAL-083 437
VB-111 437
10.2% 438
10.6% 438
11.6% 438
11.7% 438
11.8% 438
11.9% 438
12.2% 438
16.1% 438
18.2% 438
20.1% 438
20.4% 438
20.5% 438
20.7% 438
21.1% 438
22.5% 438
22.9% 438
24.5% 438
25.0% 438
26.7% 438
27.5% 438
28.6% 438
29.3% 438
30.7% 438
32.0% 438
3.4% 438
3.5% 438
3.6% 438
38.1% 438
3.8% 438
38.5% 438
43.6% 438
4.9% 438
54.5% 438
6.8% 438
72.5% 438
7.6% 438
7.7% 438
78.6% 438
79.3% 438
8.3% 438
8.6% 438
88.9% 438
8.9% 438
9.1% 438
9.7% 438
9.8% 438
Frequent 438
hypothyroidism 438
Non 438
None 438
accounting 439
analyses 439
analysis 439
ANOVA 439
Associations 439
avg 439
backward 439
binomial 439
calculate 439
calculated 439
categorical 439
chi 439
Chi 439
chi-square 439
Chi-square 439
chi-squared 439
Chi-squared 439
ciation 439
ciations 439
Comparisons 439
confounding 439
constructed 439
correction 439
Correlations 439
Descriptive 439
distributions 439
estimate 439
estimated 439
exact 439
Exact 439
Fifty 439
Fisher 439
generalized 439
Individual 439
justed 439
Kaplan 439
Kruskal-Wallis 439
linear 439
log 439
Log 439
logistic 439
Logistic 439
Mann-Whitney 439
mated 439
Meier 439
method 439
model 439
models 439
Pearson 439
Poisson 439
Propensity 439
p-values 439
rank 439
Rank 439
regressions 439
SAS 439
square 439
statistics 439
test 439
tests 439
tinuous 439
trees 439
T-test 439
t-tests 439
utilized 439
variables 439
variance 439
variate 439
Wilcoxon 439
DOCE 440
FOLFIRINOX 440
gem 440
Gem 440
GEM 440
gemcitabine 440
Gemcitabine 440
GPC3 440
mPDAC 440
nab-P 440
nabP 440
Nab-P 440
nabPAC 440
nab-paclitaxel 440
pan 440
PDAC 440
TG01 440
450 441
73 441
Ex 441
IB 441
positive 441
Stage 441
299 442
CA19-9 443
FU 443
LV 443
mtx 443
nal-IRI 443
oxaliplatin 443
ablation 444
bpCR 444
comparable 444
CT-P10 444
CT-P6 444
equivalence 444
immunogenicity 444
RTX 444
safety 444
Safety 444
SB3 444
similarity 444
tolerability 444
TRZ 444
Cb 445
EC1169 445
V 445
con 446
Conclusion 446
continuation 446
ini 446
juvant 446
LET 446
Major 446
PBO 446
RIB 446
switched 446
verse 446
012 447
80405 447
AIO 447
ARCAD 447
bevacizumab 447
CALGB 447
chemorefractory 447
CO 447
FIRE-3 447
fluoropyrimidine 447
FOLFOXIRI 447
FP 447
Klinikum 447
K-ras 447
KRK 447
MCRC 447
Munich 447
NCCTG 447
nd-line 447
Norris 447
panitumumab 447
Second 447
Southern 447
third-line 447
Timothy 447
Treatments 447
years-old 447
antiangiogenic 448
aRCC 448
axitinib 448
cabo 448
Cabo 448
cabozantinib 448
clear-cell 448
eve 448
EVE 448
everolimus 448
IMDC 448
lenvatinib 448
METEOR 448
mRCC 448
multikinase 448
nephrectomy 448
Nx 448
RCC 448
renal 448
Renal 448
Rini 448
SOR 448
sunitinib 448
Sunitinib 448
uHCC 448
Accurate 449
ALND 449
avoided 449
Ax 449
BCT 449
BCT-E 449
cN0 449
cosmesis 449
curettage 449
Db 449
dissection 449
extremity 449
fewer 449
fibrosis 449
limb 449
LNE 449
lobectomy 449
loco-regional 449
lumpectomy 449
lymph 449
mastectomy 449
micrometastasis 449
Mx 449
node 449
node-negative 449
nodes 449
omission 449
operation 449
pN0 449
postoperatively 449
reconstruction 449
re-excision 449
regional 449
Resection 449
retroperitoneal 449
sentinel 449
SLNB 449
SLYMPHA 449
SN 449
surgeons 449
unilateral 449
change 450
Cumulative 450
Forty 450
Minimum 450
RR 450
114 451
115 451
117 451
123 451
128 451
129 451
142 451
143 451
156 451
164 451
165 451
167 451
169 451
170 451
172 451
176 451
182 451
183 451
184 451
186 451
187 451
188 451
195 451
196 451
197 451
199 451
201 451
203 451
204 451
207 451
214 451
215 451
218 451
223 451
227 451
228 451
242 451
291 451
315 451
472 451
478 451
577 451
Colorectal 451
Gastrointestinal 451
diabetes 452
elevated 452
Elevated 452
GI 452
lactate 452
LDH 452
nasal 452
POD24 452
pressure 452
ACRIN 453
ANZUP 453
AstraZeneca 453
Canadian 453
CCTG 453
ClinicalTrials 453
cooperative 453
enrolling 453
FORWARD 453
funded 453
Funded 453
gov 453
grant 453
grants 453
ID 453
investigator-initiated 453
Korean 453
Multicenter 453
NCI 453
NCI-sponsored 453
NCTN 453
NIH 453
Pharmaceuticals 453
previously-treated 453
single-center 453
sponsored 453
SqNSCLC 453
sub-study 453
SWOG 453
translational 453
Trial 453
Trials 453
umbrella 453
160 454
ad 454
UC 454
vanced 454
101 455
208 455
222 455
270 455
280 455
301 455
309 455
323 455
370 455
393 455
410 455
428 455
437 455
462 455
468 455
506 455
550 455
583 455
Central 455
Comparison 455
Evaluation 455
MDACC 455
Nervous 455
Panel 455
System 455
Tumors 455
10% 456
11% 456
13% 456
15% 456
17% 456
18% 456
19% 456
20% 456
22% 456
23% 456
2% 456
25% 456
26% 456
29% 456
30% 456
32% 456
33% 456
3% 456
35% 456
36% 456
39% 456
42% 456
43% 456
44% 456
4% 456
45% 456
46% 456
48% 456
49% 456
50% 456
51% 456
53% 456
54% 456
5% 456
55% 456
60% 456
61% 456
62% 456
63% 456
64% 456
65% 456
66% 456
67% 456
71% 456
77% 456
9% 456
App 456
Eighteen 456
spectively 456
accruing 457
blind 457
controlled 457
Design 457
designed 457
double 457
double-blind 457
double-blinded 457
efficacy 457
EudraCT 457
evaluates 457
evaluating 457
II 457
III 457
initiated 457
investigating 457
label 457
multi-arm 457
multi-center 457
multicenter 457
multi-centre 457
multicentre 457
multi-cohort 457
multinational 457
non-randomized 457
nonrandomized 457
Open 457
open-label 457
phase 457
Phase 457
placebo 457
placebo-controlled 457
randomised 457
randomized 457
Randomized 457
randomizing 457
single-arm 457
study 457
trial 457
two-arm 457
AR-FL 458
Clearance 458
concentration 458
concentrations 458
E2 458
FSH 458
genotypes 458
Let 458
levels 458
LLOQ 458
MW 458
NETest 458
OHD 458
pg 458
PlGF 458
PQI 458
pre-chemo 458
Serum 458
timepoint 458
VEGF-C 458
VEGFR2 458
18.9% 459
26.5% 459
6.5% 459
abdominal 459
Acute 459
adrenal 459
arterial 459
bleeding 459
bowel 459
common 459
commonest 459
complication 459
digestive 459
disorder 459
disturbance 459
edema 459
effusion 459
embolism 459
fistula 459
gastrointestinal 459
gravis 459
hematological 459
hemorrhage 459
Hepatic 459
injury 459
interstitial 459
kidney 459
mild 459
mucosal 459
myasthenia 459
neuro 459
perforation 459
pericardial 459
pulmonary 459
Rectal 459
reflux 459
skin 459
thromboembolism 459
thrombosis 459
tract 459
urinary 459
venous 459
chemo 460
chest 460
CT 460
ACP 461
address 461
advance 461
agreed 461
APMs 461
assistance 461
barriers 461
Barriers 461
cancer-specific 461
caregiver 461
caregivers 461
coaching 461
comfort 461
comfortable 461
communication 461
Communication 461
concerns 461
conflicts 461
contingent 461
conversations 461
decedents 461
discussions 461
doctor 461
education 461
educational 461
employment 461
engage 461
EOL 461
experiences 461
federal 461
financial 461
Financial 461
FoCR 461
goals 461
GoC 461
health 461
HS 461
interventions 461
interviewed 461
interviews 461
issues 461
Likert 461
lives 461
Many 461
PCP 461
PCPs 461
perceived 461
physicians 461
planning 461
preference 461
preferences 461
professional 461
PROQOL 461
provider 461
providers 461
questions 461
rated 461
ratings 461
SCPs 461
services 461
specialist 461
spouses 461
survey 461
surveyed 461
surviving 461
survivorship 461
Survivorship 461
topics 461
underserved 461
wealth 461
accessible 462
histologically 462
histopathological 462
history 462
Human 462
Normal 462
proven 462
tological 462
Daily 463
edition 463
EDT 463
Extended 463
final 463
Friday 463
Monday 463
News 463
Onsite 463
printed 463
Saturday 463
Special 463
Sunday 463
supplement 463
text 463
33 464
69 464
abstr 464
Eur 464
Int 464
Platinum 464
suppl 464
Taxane 464
ARA 465
ARAs 465
ASA 465
aspirin 465
Because 465
beta 465
full-dose 465
IFR 465
nanoparticles 465
non-users 465
p16 465
sparing 465
tested 465
users 465
AAS 466
Belfast 466
Bristol 466
Cambridge 466
Development 466
ETOP 466
Foundation 466
Glasgow 466
Haematology 466
Ian 466
Ireland 466
King 466
Kingdom 466
London 466
Manchester 466
Marsden 466
Neuroendocrine 466
NHS 466
Nottingham 466
Queen 466
Royal 466
States 466
Sutton 466
Trust 466
Tumour 466
tumours 466
UK 466
Unit 466
United 466
urgent 466
894999 467
analog 467
arginase 467
AZD3965 467
BAL101553 467
BAL27862 467
BGB-290 467
BI 467
BO-112 467
CDK9 467
DRD2 467
eFT508 467
ETC-159 467
exposures 467
HSP90 467
IR 467
molecule 467
NCT02490800 467
OHOA 467
onalespib 467
ONC201 467
oxygen 467
Pharmacokinetic 467
PTC596 467
RNR 467
TCC 467
transporter 467
differential 468
distinct 468
high-grade 468
load 468
mutational 468
original 468
pared 468
revealed 468
series 468
Apatinib 469
AXL 469
BCL-2 469
bioavailable 469
BLU-285 469
Bruton 469
BTK 469
CSF1R 469
ENTO 469
first-in-class 469
hibitor 469
inhibitor 469
irreversible 469
JAK 469
kinase 469
Kinase 469
kinases 469
larotrectinib 469
Larotrectinib 469
Nintedanib 469
once-daily 469
PDGFR 469
potent 469
Regorafenib 469
RX-3117 469
selective 469
small-molecule 469
SYK 469
tyrosine 469
Tyrosine 469
VEGFR-2 469
venetoclax 469
Abramson 470
Ahmed 470
Alexandre 470
Amsterdam 470
Anne 470
Anthony 470
Baltimore 470
Baylor 470
Benjamin 470
Bernard 470
Brenner 470
Brian 470
Center 470
Chan 470
Chen 470
Columbus 470
David 470
determinants 470
Diseases 470
Division 470
E. 470
ECOG-ACRIN 470
Emily 470
Eric 470
Gaithersburg 470
Geffen 470
Georgetown 470
Glioblastoma 470
Groningen 470
Hall 470
Hematology 470
Hershey 470
James 470
Jason 470
Jennifer 470
Jessica 470
Jonathan 470
Kelly 470
Kimmel 470
Lauren 470
Lin 470
Liu 470
Lombardi 470
M. 470
Marie 470
Maryland 470
Medi 470
Medical 470
Neurology 470
non-small 470
Ohio 470
Patrick 470
Paul 470
Pennsylvania 470
Richard 470
S. 470
Scott 470
Sidney 470
Southwestern 470
Stephen 470
Thomas 470
Zurich 470
HDI 471
ipi10 471
ipi3 471
ipi 471
nivo 471
adoptive 472
AM0010 472
anti-CTLA4 472
anti-PD-1 472
anti-PD1 472
CVA21 472
DNX-2401 472
EnAd 472
ICOS 472
IL-10 472
immu 472
immunological 472
INO-3112 472
intratumoral 472
Ipi 472
LAG-3 472
MCC 472
NCT02009449 472
NKTR-214 472
oligoclonal 472
T 472
T-cell 472
ascites 473
ative 473
B-cells 473
Bim 473
blood 473
CARTmeso 473
CCR7 473
CD16 473
CD56 473
corre 473
count 473
counts 473
cytokines 473
cytometry 473
ELISA 473
ELISPOT 473
FACS 473
flow 473
IL-6 473
immunophenotyping 473
inflammation 473
LGL 473
lymphocyte 473
manufactured 473
MDSCs 473
measured 473
monocyte 473
mononuclear 473
on-treatment 473
PA2024 473
Paired 473
PB 473
PBL 473
PBMC 473
PBMCs 473
peripheral 473
Peripheral 473
pre 473
pre-dose 473
Pre-treatment 473
Pretreatment 473
product 473
qPCR 473
sPD-L1 473
urine 473
WB 473
295 474
aNon-CRC 474
called 474
capture 474
enables 474
generation 474
Generation 474
identification 474
Next 474
patient-specific 474
platform 474
Sequencing 474
U. 474
utilizing 474
Wisconsin 474
ana 475
del 475
E 475
en 475
G12C 475
G. 475
P1 475
Co 476
Fi 476
ical 476
ight 476
ized 476
NMSC 476
observational 476
Plenary 476
prevention 476
rst 476
supplementation 476
thor 476
Torino 476
Tuebingen 476
vitamin 476
Vitamin 476
177 477
617 477
amenable 477
antagonists 477
biochemically 477
Concomitant 477
dosimetry 477
FES 477
Ga-OPS202 477
GaPSMA 477
hormone-sensitive 477
Imaging 477
Lu 477
LuPSMA 477
progressing 477
PSMA 477
somatostatin 477
sys 477
Treat 477
0% 478
15.4% 478
15.8% 478
16.5% 478
19.4% 478
20.0% 478
21.4% 478
30.0% 478
35.7% 478
37.1% 478
42.9% 478
46.4% 478
46.7% 478
60.0% 478
66.7% 478
67.3% 478
70.0% 478
71.4% 478
92.3% 478
CRT45 478
CRT75 478
dropped 478
low 478
RT50 478
salvaged 478
AA 479
AAP 479
abi 479
Abi 479
ABI 479
abiraterone 479
Abiraterone 479
acetate 479
AR-V7 479
ARV7 479
cabazitaxel 479
castrate-resistant 479
castration 479
castration-resistant 479
CBZ 479
chemotherapy-na 479
chemotherapy-naive 479
CRPC 479
declines 479
DOC 479
Enz 479
ENZ 479
enza 479
ENZA 479
enzalutamide 479
Gal 479
Grande 479
hormonal 479
mCRPC 479
Men 479
NAs 479
NHA 479
ONA 479
prednisone 479
prostate-specific 479
PSA 479
Ra-223 479
REO 479
rPFS 479
stline 479
Trop-2 479
CVC 480
EC 480
endometrial 480
inadequate 480
mation 480
prospectively 480
decrease 481
decreased 481
dimensional 481
gression 481
ilorasertib 481
measurement 481
month 481
nadir 481
pro 481
rise 481
shrinkage 481
st 481
tumour 481
179 482
sample 482
SOX 482
Thirty 482
31.8% 483
APC 483
ATM 483
BAP1 483
BARD1 483
BRCA1 483
BRCA1-like 483
BRCA2 483
BRCA-like 483
BRIP1 483
carriers 483
carry 483
causative 483
CDH1 483
CHEK2 483
deleterious 483
Deleterious 483
FANCA 483
gBRCA1 483
germline 483
hypermethylation 483
I1307K 483
Lynch 483
MLH1 483
Moderate 483
MSH2 483
MSH6 483
MUTYH 483
NBN 483
non-BRCA1 483
PALB2 483
PMS2 483
POLE 483
putative 483
PV 483
PVs 483
RAD50 483
RAD51 483
RAD51C 483
RAD51D 483
VHL 483
actions 484
addressed 484
anticoagulation 484
application 484
carefully 484
cold 484
corticosteroid 484
etiology 484
Feasibility 484
functions 484
illness 484
measuring 484
minimize 484
mitigate 484
mitigation 484
multimodal 484
nutritional 484
prophylactic 484
psychosocial 484
reduce 484
sequelae 484
Some 484
topical 484
understood 484
vital 484
exposure 485
kappa 485
left 485
V1 485
V2 485
AR 486
mul 486
multi 486
pancreatic 486
separate 486
ticenter 486
addressing 487
allocation 487
An 487
collaboration 487
collaborative 487
consortium 487
ensure 487
formal 487
IDEA 487
initiate 487
international 487
participation 487
physician 487
SCA 487
ternational 487
treat 487
treating 487
BMD 488
CTRL 488
denosumab 488
femoral 488
hip 488
hVITD 488
hypogonadal 488
lumbar 488
Older 488
rVITD 488
spine 488
testosterone 488
T-group 488
TTh 488
VITD 488
0.1% 489
0.2% 489
0.3% 489
0.4% 489
0.5% 489
0.6% 489
0.7% 489
0.8% 489
10.4% 489
1.0% 489
1.2% 489
13.1% 489
13.4% 489
1.3% 489
1.4% 489
1.5% 489
1.6% 489
17.2% 489
17.9% 489
18.7% 489
1.9% 489
2.0% 489
2.3% 489
2.4% 489
2.6% 489
3.1% 489
4.4% 489
5.7% 489
5.9% 489
7.2% 489
7.4% 489
7.8% 489
HRR 489
Prevalence 489
1970 490
765 490
About 490
annual 490
diagnoses 490
females 490
incident 490
LCS 490
males 490
Over 490
people 490
periods 490
person 490
YAs 490
586 491
compensatory 491
EEC 491
FH 491
FM 491
frameshift 491
fs 491
GA 491
harbored 491
histories 491
incidental 491
indel 491
kindreds 491
LPV 491
missense 491
MSAF 491
muts 491
nonsense 491
Number 491
pathogenic 491
Pathogenic 491
reading 491
RevGA 491
SNVs 491
somatic 491
sporadic 491
terations 491
uncertain 491
USC 491
variant 491
variants 491
34.5% 492
age 492
Among 492
Caucasian 492
female 492
Female 492
GU 492
hx 492
male 492
Male 492
Most 492
primaries 492
R-P 492
smoker 492
smokers 492
smoking 492
69.5% 493
ations 493
BRAF-V600E 493
BRAF-WT 493
Cluster 493
CMS1 493
CMS2 493
CMS3 493
CMS4 493
evident 493
H3 493
KIAA1549-BRAF 493
NF1 493
pLGG 493
Anderson 494
Dallas 494
Houston 494
MD 494
Texas 494
TX 494
accumulation 495
BTZ 495
CSC 495
fold 495
GNA 495
markedly 495
Metformin 495
mice 495
pharmacological 495
slower 495
Specifically 495
tail 495
translated 495
087 496
Ali 496
Amcasertib 496
AMG 496
ASN002 496
AZD1775 496
basket 496
BBI608 496
buparlisib 496
BYL719 496
CC-90003 496
CsA 496
CVM-1118 496
CWP291 496
DAB 496
DTRM-12 496
DTRM-555 496
entospletinib 496
erated 496
escalating 496
GS-4059 496
GSK2141795 496
INCB054828 496
lead-in 496
lomustine 496
LY3009120 496
M3814 496
MCM 496
mEC 496
MLN8237 496
oral 496
orally 496
QD 496
RIBO 496
selumetinib 496
sirolimus 496
SRA737 496
TAK-659 496
TAS-116 496
tered 496
tipiracil 496
tol 496
TP53WT 496
Trametinib 496
trifluridine 496
triplet 496
tucatinib 496
Up 496
androgen 497
Androgen 497
androgens 497
antagonist 497
bromodomain 497
castrate 497
CBP 497
CCS1477 497
deprivation 497
Enzalutamide 497
ERG 497
HSD3B1 497
N-terminal 497
ODM-201 497
p300 497
pre-surgical 497
quired 497
resistant 497
synthesis 497
Treatment 498
Based 499
COMPARZ 499
IO 499
LTR 499
PAZ 499
reduced 499
SUN 499
